Minimalistic 5’-UTRs and segmented poly(A) tails by Trepotec, Željka
 Aus der Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital 
der Ludwig-Maximilians-Universität München 
 
 
Direktor: Prof. Dr. Dr. med. Christoph Klein 
 
 
 
Minimalistic 5’-UTRs and segmented poly(A) tails  
– a step towards increased potency of transcript 
therapies 
 
Dissertation 
zum Erwerb des Doktorgrades der Naturwissenschaften an der Medizinischen 
Fakultät der Ludwig-Maximilians-Universität zu München 
 
 
Željka Trepotec 
aus Koprivnica, Kroatien 
 
 
2019
 i 
Mit Genehmigung der Medizinischen Fakultät  
der Universität München 
 
 
 
Betreuer:     PD. Dr. Carsten Rudolph 
 
Zweitgutachter:    Prof. Dr. Andreas Ladurner 
 
Prüfungsausschuss:  Prof. Dr. Peter B. Becker 
     Prof. Dr. Alexander Faussner 
 
Dekan:     Prof. Dr. med. dent. Reinhard Hickel 
 
 
 
Tag der mündlichen Prüfung:    September 27, 2019 
  
 ii 
Eidesstattlicher Versicherung 
 
 
 
 
Trepotec, Željka 
 
Ich erkläre hiermit an Eides statt, dass ich die vorliegende Dissertation mit dem Thema 
 
 
 
Minimalistic 5’-UTRs and segmented poly(A) tails – a step towards 
increased potency of transcript therapies 
 
 
 
selbständig verfasst, mich außer der Angegebenen keine weiteren Hilfsmittel bedient und alle 
Erkenntnisse, die aus dem Schrifttum ganz oder annähernd übernommen sind, als solche kenntlich 
gemacht und nach ihrer Herkunft unter Bezeichnung der Fundstelle einzeln nachgewiesen habe. 
 
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder in ähnlicher 
Form bei einer anderen Stelle zur Erlangung eines akademischen Grades eingereicht wurde. 
 
 
 
 
 
München, 16.10.2019 
 
 
 
_______________________________ 
Željka Trepotec 
 
 iii 
 
 
 
 
 
 
 
 
To my beloved parents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
 
 
 
 
 
 
 
“Da mi je samo znati, Draš, kaj ti zaprav misliš, gda si kaniš poštenoga posla najti?“ 
-“Ah, kaj ja znam Regica… Sem čuda put probal al sigde za kvalifikacije pitaju.” 
  
Božja vola, prva priča 
Gruntovčani 
SUMMARY 
v 
 
Studies in the past decade have brought to light the therapeutic potential of transcript therapies as 
an alternative to classical gene therapy. In contrast to DNA, which has to be delivered to the nucleus 
of the cell to assure the production of the mRNA transcript and its translation in the cytoplasm, 
mRNA’s target delivery location is the cytoplasm. Thus, unlike in DNA-based gene therapies, there is 
no risk of insertional mutagenesis when using mRNA-based transcript therapies. Transient translation 
of delivered mRNA is associated with its attributes such as degradation through physiological 
pathways. Apart from that, intrinsic immunogenicity is another attribute normally associated with 
mRNA. These challenges have been overcome by optimizing the structural elements (e.g. 
untranslated regions, poly(A) tail and/or usage of chemically modified nucleotides). Chemically 
modified mRNAs, therefore, emerge as a safer promising tool for transcript therapy.  
The first part of the thesis is focused on the design of synthetic minimalistic 5’-UTRs containing 
sequence elements essential for mRNA production using T7 RNA polymerase and their efficient 
translation. Such synthetic UTRs were benchmarked against some of the conventionally used UTR 
sequences, such as human alpha-globin. To achieve the goal of finding the very minimal synthetic 5’-
UTR, harboring features of sufficient expression but resistant to structural changes upon chemical 
modification, following approaches were investigated. Several luciferase-encoding unmodified and 
chemically modified mRNAs harboring minimal synthetic 5’-UTRs were investigated upon 
transfection in cell culture and in vivo in mice. A particularly short 5’-UTR, consisting of only 14 
nucleotides between the T7 promoter and Kozak consensus sequence, yielded similar or even higher 
expression than a 37 nucleotides long human alpha-globin 5’-UTR containing mRNA in HepG2 and 
A549 cells. The functionality of translation regulators, namely Kozak and TISU element, were affected 
by the choice of modified nucleotides. Minimal 5’-UTRs identified in the in vitro experiments also 
performed better than the human alpha-globin 5’-UTR in vivo, what was confirmed by 
bioluminescence imaging of luciferase expression in mouse livers at 6h post-intravenous injection of 
a lipidoid nanoparticle-formulated RNA in female Balb/c mice. To rule out sequence-specific effects, 
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promising UTRs were also combined with hEPO. Minimal TISU-containing 5’-UTR hEPO mRNA 
reached elevated levels in supernatants from A549 cells post-transfection when compared to 
commonly used 5’-UTR benchmarks. Taken together, two promising candidates of synthetic 
minimalistic 5’-UTRs for use in transcript therapies were identified.  
In the second study, the focus was set on poly(A) tail, a common structural feature of all cellular 
messenger RNAs (with the exception of histone protein-coding mRNAs). As therapeutic mRNA is 
transcribed in vitro, poly(A) can either be brought via the DNA template (PCR or plasmid-based) or 
added to the mRNA enzymatically, in a separate post-transcriptional step. A plasmid containing 
poly(A) tail enables easier and cheaper template production, but such homopolymeric regions 
recombine in E.coli, causing extensive shortening of the poly(A) tail. The segmented poly(A) 
approach, defined as at least two A-containing elements, each defined as a nucleotide sequence 
consisting of 40 – 60 adenosines, separated by a spacer element of different length, was investigated 
with respect to recombination of plasmids in E.coli and the potency of the poly(A)-containing mRNAs. 
Incorporation of those resulted in significant reduction of plasmid recombination in E.coli, without 
any negative effect on either mRNA half-life or protein expression. The effect was confirmed for 
sequences of varying length: d2EGFP (0.9 kb), firefly luciferase (1.7 kb), hEPO (0.9 kb) and CFTR (4.5 
kb), proving the adaptability of the segmented poly(A) approach with 6 nucleotides as a spacer for 
different therapeutic targets (intracellular proteins: d2EGFP and luciferase; secretory protein: hEPO 
and transmembrane protein: CFTR). Promising results with physiological genes led to further 
investigation of the effect of the increased spacer length on the performance of segmented 
poly(A)2x60. 
Luciferase constructs with longer spacers of 12 and 24 nucleotides revealed higher translation 
efficiencies compared to widely used homogeneous poly(A) tail of 120 adenosines, preceded with 
reduced recombination rates in E.coli. Reducing the spacer length to a single nucleotide (either C, G 
or T) resulted in higher luciferase expression, and particularly the incorporation of a single G further 
reduced poly(A) recombination to zero. Significantly reduced recombination in E.coli with either 
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comparable or higher translation efficiencies of the resulting mRNA presents segmented poly(A) as 
an attractive alternative to the classical homogeneous poly(A)>100 bp, thereby facilitating plasmid-
based template production. Results obtained in the current work allow the conclusion that 
segmented poly(A)2x60 with either 6 or 1 nucleotide spacer, in plasmid vectors, significantly reduces 
recombination in E.coli without negatively affecting translation and mRNA stability when compared 
to the widely used poly(A)120. 
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Studien im letzten Jahrzehnt haben das therapeutische Potential der Transkript-Therapie als 
Alternative zur klassischen Gentherapie deutlich gemacht. Im Gegensatz zum DNA-basierten Ansatz, 
bei dem für die mRNA Produktion der Zellkern erreicht werden muss, müssen mRNAs lediglich ins 
Zytoplasma transportiert werden. Demzufolge besteht bei der Verwendung von mRNA Transkripten, 
im Gegensatz zu DNA-basierten Therapien, kein Risiko einer Insertionsmutagenese. Herkömmliche 
Probleme die der mRNA zugeordnet werden sind die intrinsische Immunogenität und kurzlebige 
Translation der gelieferten mRNA aufgrund ihres physiologischen Abbaus. Diese Herausforderungen 
können durch Optimierung der mRNA Strukturelemente (z.B. nicht translatierte Regionen, poly(A)-
Schwanz und/oder Verwendung chemisch modifizierter Nukleotide) überwunden werden. Zum 
Beispiel sind chemisch modifizierte mRNAs ein sichereres und vielversprechenderes Werkzeug für die 
Transkript-Therapie.  
Der erste Teil dieser Doktorarbeit konzentriert sich auf das Design und die effiziente Translation 
synthetischer minimalistischer 5’-UTRs, welche Sequenzelemente für die mRNA-Produktion unter 
Verwendung von T7-RNA-Polymerase enthalten. Diese synthetischen UTRs wurden mit herkömmlich 
verwendeten UTR-Sequenzen wie der humanem Alpha-Globin-UTR verglichen. Um minimale 
synthetische 5’-UTR mit ausreichender Expression zu finden, welche durch chemischen 
Modifikationen gegen strukturelle Veränderungen resistent sind, wurden folgende Ansätze 
untersucht. Mehrere Luciferase-kodierende, unmodifizierte und chemisch modifizierte mRNAs mit 
minimalen synthetischen 5’-UTRs wurden nach Transfektion in vitro und in vivo in Mäusen 
untersucht. Eine besonders kurze 5’-UTR, die aus nur 14 Nukleotiden zwischen dem T7-Promotor und 
der Kozak-Konsensussequenz besteht, ergab eine ähnliche oder sogar höhere Expression als eine 
humane alpha-Globin-5’-UTR mRNA mit 37 Nukleotiden in HepG2- und A549-Zellen. Die 
Funktionalität der Translationsregulatoren, nämlich der Kozak- und TISU-Elemente, wurde durch die 
Wahl der modifizierten Nukleotide beeinflusst. Minimale 5’-UTRs, die in den in vitro-Experimenten 
identifiziert wurden, zeigten ebenfalls in vivo eine Verbesserung gegenüber der humanen Alpha-
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Globin-5’-UTR, was durch die Luciferase-Expression in Mausleber 6 Stunden nach intravenöser 
Injektion einer Lipidoid-Nanopartikel-formulierten mRNA in weiblichen Balb/c-Mäusen bestätigt 
wurde. Um sequenzspezifische Effekte auszuschließen, wurden auch vielversprechende UTRs mit 
hEPO kombiniert. Im Vergleich zu üblicherweise verwendeten 5’-UTR-Benchmarks wurde mit 
minimaler TISU, 5’-UTR-hEPO mRNA ein höherer Gehalt in Überständen von transfizierten A549-
Zellen festgestellt. Zusammenfassend kann festgehalten werden, dass zwei vielversprechende 
Kandidaten synthetisch minimalistischer 5’-UTRs zur Verwendung in Transkript-Therapien 
identifiziert wurden. 
Im zweiten Teil lag der Fokus auf dem poly(A)-Schwanz, einem Strukturmerkmal aller zellulären 
mRNA (mit Ausnahme der mRNA-codierenden Histonproteine). Da therapeutische mRNA in vitro 
transkribiert wird, kann der poly(A)-Schwanz entweder über die DNA-Matrize (auf PCR- oder 
Plasmidbasis) oder enzymatisch in einem separaten posttranskriptionellen Schritt zur mRNA 
hinzugefügt werden. Plasmide, die einen poly(A)-Schwanz enthalten ermöglichen eine einfachere 
und billigere Matrizenherstellung, jedoch neigen diese homopolymeren Regionen zur Rekombination 
in E. coli, was zu einer starken Verkürzung des poly(A)-Schwanz führt. Ein segmentierter poly(A)-
Ansatz (mindestens zwei A-haltige Elemente, jeweils definiert als Nukleotidsequenz bestehend aus 
40 - 60 Adenosinen, getrennt durch ein Spacerelement unterschiedlicher Länge) wurde hinsichtlich 
der Rekombination von Plasmiden in E. coli und die Aktivität der poly(A)-haltigen mRNAs untersucht. 
Der Einbau von diesen führte zu einer signifikanten Reduktion der Plasmidrekombination in E. coli, 
ohne dass die mRNA-Halbwertszeit oder die Proteinexpression negativ beeinflusst wurden. Die 
Wirkung wurde für Sequenzen unterschiedlicher Länge bestätigt: d2EGFP (0,9 kb), Firefly-Luciferase 
(1,7 kb), hEPO (0,9 kb) und CFTR (4,5 kb), was die Anpassungsfähigkeit des segmentierten poly(A)-
Ansatzes mit 6 Nukleotiden als ein Spacer für verschiedene therapeutische Ziele zeigt (intrazelluläre 
Proteine: d2EGFP und Luciferase; sekretorisches Protein: hEPO und Transmembranprotein: CFTR). 
Vielversprechende Ergebnisse mit physiologischen Genen führten zu weiteren Untersuchungen des 
Einflusses der erhöhten Spacerlänge auf die Leistung von segmentiertem poly(A)2x60. Luciferase-
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Konstrukte mit längeren Spacern von 12 und 24 Nucleotiden zeigten höhere Translationseffizienzen 
gegenüber einem weit verbreiteten homogenen poly(A)-Schwanz von 120 Adenosinen, denen in E. 
coli reduzierte Rekombinationsraten vorausgingen. Das Reduzieren der Spacer-Länge auf ein 
einzelnes Nukleotid (entweder C, G oder T) führte zu einer höheren Luciferase-Expression, 
insbesondere wurde durch den Einbau eines einzelnen G die poly(A)-Rekombination vermieden. 
Durch die signifikant reduzierte Rekombination in E. coli mit vergleichbarer oder höherer 
Translationseffizienz der resultierenden mRNA stellt ein segmentierter poly(A)-Schwanz eine 
attraktive Alternative zu dem klassischen homogenen poly(A)> 100 bp dar und erleichtert so die 
Plasmid-basierte Matrizen-Produktion. Die in der aktuellen Arbeit erzielten Ergebnisse lassen den 
Schluss zu, dass segmentiertes poly(A)2x60 mit entweder 6 oder 1 Nukleotid-Spacer im Vergleich zu 
einem weit verbreiteten poly(A)120 die Rekombination der Plasmidvektoren in E. coli signifikant 
reduziert ohne die Translation und die mRNA-Stabilität negativ zu beeinflussen. 
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Although the function of modern organisms is orchestrated by biomolecules, namely proteins, lipids, 
carbohydrates, DNA and RNA, there is a compelling hypothesis that the earliest scions of life stored 
and propagated genetic information only via RNA molecules.1 In this conceptual idea called RNA 
world2–4, the primordial RNA genome independently replicated in a cooperative manner that set up 
the basics for the complexity during the early evolution of life, in a distant evolutionary past, 
approximately 4 billion years ago (Figure 1)4. The key molecule that could have supported such an 
evolving fundamental genetic system with the defining hallmarks of life, heredity, and evolution, was 
the RNA. With the ground-breaking discovery of ribonuclease P catalysts5, self-splicing introns6 in the 
1980s and later RNA-catalyzed RNA polymerization7, it was proved that RNA also has an additional, 
enzymatic property. Being able to store genetic information and catalyze peptide bond in the 
ribosome8,9 as well as the transcription of an active ribozyme10, it is a legitimate candidate for such a 
hypothesis.  
Later, as the evolution of new biomolecules and selective pressure at the molecular level took place, 
there was a role splitting for features that solely RNA harbored. DNA took over the role of a template 
molecule of genetic material11, due to a higher replication fidelity, greater stability under hydrolytic 
conditions12 and rigidness to prevent self-folding13. Proteins, however, found a niche in driving 
enzymatic and chemical reactions, due to the whole spectrum of their structural diversity.14 
However, the role of an intermediary of genetic information transfer still belongs to the RNA. As it 
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used to be that the RNA gene is instructed for the synthesis of a corresponding ribozyme, now the 
same mechanism is adapted in the process of genome replication.14 Therefore, the RNA molecules 
can be considered as molecular fossils. 
 
 
Figure 1. Timeline of the early events in Earth’s history, dating billions of years ago.  
The RNA world supposedly appeared ~3.8 billion years ago. Figure adapted from Joyce, 2002.4 
 
 
This molecular fossil, the molecule of RNA which persevered from the far past till today due to its 
properties, is still the central molecule of all forms of life.15 It is the core of the central dogma of 
molecular biology, enunciated by F. Crick in 1958.16 Accepting the premise that DNA provides the 
coding information for genes transcribed into intermediary molecule, which is then translated into 
protein, the conclusion that follows is that the genes are the “blueprint for life”.17,18 That 
intermediary molecule, a portion of the total cellular RNA carrying genetic information from nuclear 
DNA to cytoplasmic ribosomes, was named “messenger RNA” (mRNA) by Francis Jacob and Jacques 
Monod in 1961.19  
mRNA carries its role as a single-stranded molecule, with a possibility to form great structural 
diversity just by folding onto itself.20 Therefore, it harbors many cellular functions, although the most 
important one is the transmission of information. It consists of four building blocks: adenosine 5’-
monophosphate (AMP), guanosine 5’-monophosphate (GMP), cytidine 5’-monophosphate (CMP) and 
uridine 5’-monophosphate (UMP).21 Eukaryotic mRNAs, with some exceptions, harbor cap at 5’ end, 
a residue of 7-methylguanosine linked to the 5’-terminal residue of the molecule by 5’-5’-
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triphosphate bond. It protects the molecule from ribonuclease cleavage but also enables recognition 
of the ribosome which leads to initiation of the translation.22–24  Cap also plays an important role in 
the export of mRNA from the nucleus.24,25 
At the 3’ end, there is a string of 80 to 120 adenosines, forming the protective poly(A) tail. Among the 
protective role of the poly(A) against enzymatic destruction, it also helps to stabilize the molecule26, 
exporting it from the nucleus27, localizing it intracellularly and initiating the translation28,29. Both 
protective structures at each end of the naturally occurring mRNAs are attached enzymatically, 
during or shortly after transcription. The coding region is a central part of the mRNA molecule; 
composed of codons that are in turn translated into functional proteins. This core of the molecule is 
flanked by an untranslated region (UTR) from each side. As the name suggests, they are not 
translated, but their sequence defines their function in the molecule: altering the translation 
efficiency, mRNA stability and localization.30–35 The schematic representation of the structural 
elements of an mRNA molecule is shown in Figure 2. 
 
 
Figure 2. The structural elements of a mature mRNA transcript.  
It is composed of the m7G cap, followed by 5’-UTR, coding sequence to which 3’-UTR is continuing and at the end, poly(A) 
tail. Figure adapted from Daylite 2008. 36 
 
Events leading to gene expression are highly regulated at the cellular level. Besides transcriptional 
control, a fundamental mechanism controlling gene expression is at the post-transcriptional level 
mediated through the multiple interactions between the regulatory elements of the mRNA and RNA-
binding proteins. With respect to the mRNA structure, the numerous control points are the elements 
found within the 5’-UTR, where regulatory proteins can bind and inhibit ribosomal scanning.  
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As one of the first examples was that highly stable secondary structure can inhibit translation, but 
also structures with lower thermal energy if positioned proximally to m7G cap.37,38 Besides, 
translational efficiency was reduced with increasing GC content in 5’-UTR, if the distance to the cap 
and predicted thermal stability were held constant.39 
In the conventional cap-dependent translation, sequence elements have been described that support 
cap-independent translation of their respective genes.40,41 Another structural element found more 
commonly in viral genomes is the internal ribosome entry site (IRES element). It is widely believed 
that inclusion of such elements at the 5’-UTR, specifically IRES, initiates cap-independent mRNA 
translation by a direct ribosomal recruitment.31,42 However, due to the lack of proves to determine 
genuine IRES elements, it is impossible to recognize common features that would explain how 
internal translation is achieved.43,44  
The other end of the mRNA molecule, namely the 3’-UTR is also a target for regulation. Sequence 
and/or structural elements within are recognized both by proteins (e.g. AU-rich element binding 
protein)45 and RNAs (e.g. microRNAs)46–49. Depending upon the RNA binding partner, it can lead to 
either activation or repression of translation. RNA-binding proteins often alter translation via poly(A) 
tail, or other proteins that bind at the cap structure (e.g. initiation factor eIF4E). A small, micro RNA 
(miRNA) control gene expression either by repression of translation or by supporting mRNA 
degradation.50 On a global cellular level, gene translation is achieved through phosphorylation of the 
initiation factors, e.g. eIF2 and eIF4E, and by modulating their binding affinities.51 The overview is 
schematically shown in Figure 3. With that cognition, a whole new world of research into causes of 
diseases resulting from translational dysregulation could be established. 
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Figure 3. Regulation of eukaryotic mRNA translation occurs at numerous control points.  
At the 5’-UTR, protein expression is regulated by binding elements and proteins. At the 3’ end, poly(A) is also participating in 
the regulation of translation by PABP binding, which also participates in an interaction with cap-binding proteins. Figure 
adapted from Baker 2006. 51 
 
 
With the knowledge about the structure and function of the mRNA gained over time, we are now 
approaching its translation into a new class of therapeutics. Considering their great potential as a 
method of gene delivery, it could be used to cure genetic deficiencies and a whole spectrum of 
inherited diseases by the expression of therapeutic proteins. Transcript therapy, by definition, utilizes 
RNA as a therapeutic molecule, whether it be mRNA or small interfering RNA (siRNA), performing its 
function directly in the cytoplasm. This is just one of the conceptual advantages of transcript 
therapies over classical DNA-based gene therapy; the delivery method must overcome just one 
barrier instead of two (cytoplasm and nuclear lamina) to release the content. As the niche of DNA-
based gene therapy is indeed nucleus, there is also a risk of integration into the chromosomes via 
random insertional mutagenesis52,53, which has resulted in cancerous outcome in the past studies54,55. 
Moreover, mRNA transcripts directly utilize cellular ribosomes as bioreactors for establishing the 
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expression of the protein of interest.56 As the cell itself produces the protein of interest, correct post-
translational modifications are ensured, thereby reducing the immunogenicity of the therapeutic 
protein. This is the advantage compared to recombinant protein approach, where recombinant 
proteins expressed in heterologous systems can be recognized as foreign antigens (due to the lack of 
desirable post-translational modification(s)), therefore causing a systematic immune response by the 
host.57 Moreover, some proteins, e.g. membrane proteins or intra-organelle proteins may be 
difficult/impossible to produce in heterologous systems or their delivery to target cells/organelles 
may be limiting. Protein expression in mRNA transcript therapy is transient, due to enzymatic mRNA 
degradation over time, which makes it more attractive as a therapeutic agent, especially when 
producing antigenic proteins for vaccinations or cancer immunotherapeutics.58–62 mRNA-based 
genome editing tools are not only potent but offer safety advantages over protein-based or virus-
encoded alternatives.63  
The very first proof of concept that mRNA encoding a reporter protein has a potential therapeutic 
application was demonstrated by Wolf et al in 1990, with an intramuscular injection of mRNA into 
the mouse.64 However, only during the recent years, the field of mRNA therapeutics has progressed 
to clinical applications. From then until now, it moved from the research to the clinical trials, 
especially in the field of cancer vaccines.65–67 Improvements in mRNA delivery and the reduction of 
the mRNA’s immunogenicity enabled its diverse therapeutic applications. Examples include, but are 
not limited to induced immunity against H10N8 and H7N9 influenza viruses68, protection against Zika 
virus-induced congenital disease69, regenerative treatment for heart failure, diabetic wound healing, 
and vascular diseases70. The latter has progressed to a first clinical trial.71 As for the bone healing, 
promising options are being developed.72,73 With the mRNA technology platform, there is a possibility 
to induce pluripotent stem cells by delivering mRNA-encoded transcription factors.52 In preclinical 
models of human hereditary metabolic diseases, such as Crigler-Najjar syndrome, alpha-1-antitrypsin 
deficiency, thrombotic thrombocytopenic purpura, urea cycle disorder, mRNA transcript therapy is 
being proved as a lifesaving alternative to existing symptom-relief therapeutics.56,74–76 The timeline of 
key discoveries and clinical advances in the mRNA therapeutic field is shown in Figure 4. 
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Figure 4. Key discoveries and advances in the development of mRNA as a drug technology.  
The first demonstration of translation of naked mRNA injected into muscle tissue of mice was shown in 1990. A discovery 
that IVT mRNA with incorporated modified nucleosides is non-immunogenic happened in 2005. In 2012, a protective 
vaccination with flu-specific mRNAs entered the preclinical studies. In vivo application against virus infections was shown in 
2017. 
 
Despite the number of preclinical and clinical trials in progress, there is a need to overcome barriers 
related to mRNAs therapeutic potential and safety. To enhance its therapeutic potential, numerous 
approaches have been undertaken to reduce the innate immune activation upon delivery.58,77 
Significant reduction of mRNAs immunogenicity has been obtained with the incorporation of 
modified nucleotides.58 Kariko showed that the incorporation of pseudoU into the RNA reduces the 
immunogenicity of the RNA molecule.78 Following this idea, it was shown that synergistic decrease of 
mRNA binding to TLR3, LR7, TLR8 and RIG-I in human peripheral blood mononuclear cells could be 
achieved by the replacement of only 25% of uridines and cytidines with 2-thiouridine and 5-
methylcytidine, respectively.77 In contrast to the incorporation of modified nucleotides, Thess et al 
demonstrated the potential of sequence optimization wherein, the optimized sequences resulted in 
higher transgene expression and lower immune response when delivered as unmodified mRNA 
compared to its modified counterpart.79 To improve the translational efficiency and intracellular 
stability of the delivered mRNA, research efforts are focused on every structural feature of the 
molecule. These are presented schematically as Figure 580. 
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Figure 5. Structural modifications for tuning mRNA pharmacokinetics.  
The 5’-UTR region can be modulated by incorporating IRES elements, other regulatory sequence elements which attract 
molecules involved in translation and trafficking or inhibiting RNA degradation. By changing the length of poly(A) tail, one 
can regulate mRNA stability and translation efficiency. Figure adapted from Sahin et al, 2014. 80 
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The current thesis was aimed at designing potent mRNA molecules with a minimalistic approach. To 
this end, investigations were made into two of the critical structural elements, namely 5’-UTR and 
poly(A) tail. The first part of the dissertation focuses on 5’-UTR. Series of synthetic minimalistic UTRs 
were designed based on a rational approach to include only the essential elements needed for in 
vitro transcription by T7 RNA polymerase and efficient intracellular translation of RNA. A universal 
synthetic UTR, regardless of the encoding sequences, ideally has characteristics of being non-
immunogenic and without bearing any secondary structures, which could theoretically inhibit 
scanning mechanism. The application of minimalistic UTRs is described in Chapter 4. This part of the 
thesis has been published as “Maximizing the translational yield of mRNA therapeutics by minimizing 
5’-UTRs” in Tissue Engineering Part A, in April 2018 (DOI: 10.1089/ten.TEA.2017.0485).  
The 3’-end of the mRNA is elaborated in Chapter 5. The major aim of the undertaken work was to 
reduce recombination of plasmid vectors containing homopolymeric poly(A) regions in E.coli without 
affecting mRNA stability and translation efficiency. For this, novel poly(A) tail structures, 
implemented by creating segments of different adenosine lengths and spacers between the regions 
were investigated. It could be shown that certain segmentation of the poly(A) tail provide either 
equal or higher levels of protein production, but significantly reduce recombination of plasmid DNA 
in E.coli, without negatively affecting mRNA half-life. This part of the thesis has been accepted for 
publication as “Segmented poly(A) tails significantly reduce recombination of plasmid DNA without 
affecting mRNA translation efficiency or half-life” in RNA, in December 2019 (ID: RNA/2018/069286). 
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In Chapter 6, achieved goals and future possible approaches for effective mRNA expression in more 
complex applications are discussed. We show that, in case of therapeutic applications, synthetic 
minimalistic 5’-UTR sequences outperform some of the standard, widely used 5’-UTRs such as human 
alpha-globin. Our results on segmented poly(A) tails demonstrate their superior potential compared 
to the conventionally used homogeneous poly(A) tails with respect to recombination of the plasmids 
and the resulting mRNA performance (half-life and translational efficiency). These results taken 
together represent some of the future possibilities achievable through rational design of mRNA. 
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In the following chapter, all chemicals, devices, and software, which were used for both projects, are 
listed and described.  
 
 
 
A whole list of coding sequences and UTRs is provided in Appendix, Chapter 9.  
 
 
 
Table 1. Cell lines used 
Product  Supplier Number 
A549 cells DSMZ ACC-107 
HepG2 cells DSMZ ACC-180 
HEK293 cells DSMZ ACC-305 
CFBE cells University of Münster n/a 
16HBE14o- University of Münster n/a 
 
 
 
Table 2. Cell culture media and supplements used 
Product Supplier 
Dulbecco`s Modified Essential Medium (DMEM)/F-12, 
L-Glutamine, 15 mM Hepes 
Gibco Life Technologies 
Fetal calf serum (FCS), heat-inactivated Gibco Life Technologies 
Gentamycin Sigma Aldrich 
Minimum Essential Medium (MEM) GlutaMAX Gibco Life Technologies 
MATERIALS 
 
12 
Phosphate-buffered saline (PBS) Gibco Life Technologies 
Penicillin/Streptomycin solution Gibco Life Technologies 
Roswell Park Memorial Institute (RPMI) 1640 Medium 
(1X)+ GlutaMAX™ 
Gibco Life Technologies 
Trypsin/EDTA solution Sigma 
TrypLE™ Gibco Life Technologies 
 
 
 
Table 3. Transfection reagents used 
Product Supplier 
Lipofectamine® MessengerMAX™  Thermo Fisher Scientific 
Lipofectamine® 2000™ Thermo Fisher Scientific 
 
 
 
Table 4. Assay kits used 
Product Supplier 
NucleoSpin® Plasmid Miniprep kit Machery-Nagel 
NucleoBond® Xtra Maxi prep kit Machery-Nagel 
NucleoSpin® Gel and PCR Clean-up Machery-Nagel 
Single shot Cell Lysis kit Bio-Rad 
iScript Select cDNA Synthesis kit Bio-Rad 
 
 
 
A whole list of primers is provided in Appendix, Chapter 9. 
 
 
 
Table 5. Antibodies and detection kits used for Western Blot and staining reagent used for FACS 
Antigen Catalog # Supplier 
Primary antibodies   
        α-CFTR P13569 R&D Systems 
        α-Hsp90 TA500494 Origene 
Secondary antibodies   
        donkey-α-mouse IgG (HRP) ab6820 abcam 
Staining reagents and detection kits   
        SuperSignal™ West Femto 34095 Thermo Fisher Scientific 
        Luminata™ Crescendo Western HRP substrate WBLUR0500 EMD Millipore / Merck 
        Luminata™ Classico Western HRP substrate WBLUC0500 EMD Millipore / Merck 
        Luminata™ Forte Western HRP substrate WBLUF0500 EMD Millipore / Merck 
        Propidium iodide 11348639001  Sigma-Aldrich 
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Table 6. Chemicals used for cell culture 
Chemical Supplier 
Dimethyl sulfoxide (DMSO) Sigma Aldrich 
Ethanol Roth 
GTP New England Biolabs 
HEPES Gibco Life Technologies 
L-Glutamine Biochrome 
Potassium dihydrogen phosphate Sigma Aldrich 
Sodium chloride Roth 
Water for injection (WFI) B. Braun 
 
Table 7. Chemicals used for in vitro transcription 
Chemical Supplier 
2-Propanol Sigma Aldrich 
Adenosine triphosphate (ATP) Sigma Aldrich 
Ammonium acetate Applichem 
Bsp119l/BstBI Thermo Fisher Scientific 
Buffer Tango Thermo Fisher Scientific 
Chloroform Sigma Aldrich 
DNAse I Thermo Fisher Scientific 
Ethanol Roth 
Guanosine triphosphate (GTP) New England Biolabs 
Inorganic Pyrophosphatase Thermo Fisher Scientific 
mRNA Cap 2’-o-Methyltransferase New England Biolabs 
Poly(A) Polymerase (E.coli) NEB 
Poly(A) Polymerase Buffer NEB 
RiboLock RNase Inhibitor Thermo Fisher Scientific 
rATP Jena Biosciences 
rGTP Jena Biosciences 
rCTP Jena Biosciences 
rUTP Jena Biosciences 
5-Iodo-rUTP Jena Biosciences 
5-Iodo-rCTP Jena Biosciences 
2-thio-rUTP Jena Biosciences 
5-methyl-rCTP Jena Biosciences 
S-Methyladenosine (SAM) New England Biolabs 
Sodium acetate Roth 
T7 polymerase Thermo Fisher Scientific 
Water for injection (WFI) B. Braun 
 
 
Table 8. Other chemicals 
Chemical Supplier 
1,4-Dithiothreitol (DTT) Roth 
2-Propanol Sigma Aldrich 
2-Mercaptoethanol Sigma Aldrich 
Bovine serum albumin Sigma Aldrich 
NuPage® Antioxidant Thermo Fisher Scientific 
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NuPage® Sample Reducing Agent Thermo Fisher Scientific 
NuPAGE® SDS Running Buffer (20X) Thermo Fisher Scientific 
Tris-HCl Roth 
Triton X-100 Triton X-100 Sigma Aldrich 
Tween® Roth 
 
 
 
Table 9. Consumables used in this work 
Product Supplier 
Bolt® 4-12 % Bis-Tris Plus gels (10, 12 and 15 pockets) Thermo Fisher Scientific 
Centrifuge Tube 15 and 50 mL Corning Incorporated 
Corning® 96 Well Black Flat Bottom Polystyrene Not 
Treated Microplate 
Corning Incorporated 
Costar™ 96-Well White Plates Thermo Fisher Scientific 
Costar™ cell culture plate, flat bottom, 96, 24 and 6 wells Corning Incorporated 
Costar Microcentrifuge Tube: 0.65 mL, 1.50 mL, 2.00 mL, 
5.00 mL 
Corning Incorporated 
Costar™ Stripette 5, 10, 25, 50 mL Corning Incorporated 
Countess™ Counting Slides Thermo Fisher Scientific 
Diamond® Tipack™ D1200ST, D300ST, D200ST and DL10ST Gilson 
Eppendorf Safe-Lock Tubes 0,65; 1,7; 2,0 mL Eppendorf 
LightCycler®480 Multiwell Plate 96, white Roche 
Luminata Western HRP Merck Chemicals 
T75 Corning® cell culture flasks, angled neck, cap (vented) Sigma Aldrich 
T175 Corning® cell culture flasks, angled neck, cap (vented) Sigma Aldrich 
Trans-Blot® Turbo Transfer Pack Midi 0.2 μm PVDF Bio-Rad 
Vivaspin 20,000 kDa MWCO PES Filter Sartorius 
 
 
 
Table 10. List of technical equipment used in this work 
Name Device Supplier 
15-300 μL (12 channels), 
I39816B 
Multichannel pipette Eppendorf 
15-300 μL (8 channels), 
L29846B 
Multichannel pipette Eppendorf 
Attune® acoustic focusing 
cytometer 
Flow cytometer Thermo Fisher Scientific 
BoltR® Mini Gel Tank Gel electrophoresis tank Thermo Fisher Scientific 
Centrifuge 5810R RNA-Centrifuge Eppendorf 
ChemiDoc™ XRS System Molecular imager BIO-RAD 
Duomax 1030 Plate shaker Heidolph Instruments 
Fragment Analyzer Fragment Analyzer Advanced Analytical 
Technologies 
Hettich Mikro 220 Centrifuge Hettich Zentrifugen 
Invitrogen™ countess 
automated cell counter 
Cell counter Invitrogen™ 
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IR Sensor MCO-17AIC CO2 
Incubator 
Cell incubator Sanyo 
IVIS® Lumina XR Imaging System Caliper Life Sciences 
KDS-210-CE Dual Syringe 
Infusion/Withdrawal 
Pump 
KD Scientific 
Laminar Flow Flow BDK Luft- und Reinraumtechnik 
GmbH 
Leica DMi8 Inverted Light Microscope Leica Mikrosysteme 
Leica DM2000 LED Light Microscope Leica Mikrosysteme 
LightCycler® 96 Real-Time PCR 
System 
qPCR machine Roche 
Mastercycler® gradient Thermocycler Eppendorf 
Microcentrifuge 5415R/5415D Microcentrifuge Eppendorf 
NanoDrop2000 UV-Vis NanoDrop2000 UV-Vis Thermo Fisher Scientific 
New Brunswick™ Innova® 
Upright Freezers 
Freezer New Brunswick 
Pipetboy acu Pipette INTEGRA Biosciences AG 
PIPETMAN Classic™: 2, 20, 200 
and 1000 μl 
Pipettes Gilson 
PowerPac3000 Power supply BIO-RAD 
Reacti-Therm™ III Heating/Stirring module Pierce 
Refrigerated centrifuge 3K15 Refrigerated centrifuge Sigma 
Tecan Infinite® 200 PRO Plate reader spectrometer Tecan 
Thermomixer® compact Thermomixer C Eppendorf 
Trans-BlotR Turbo™ Transfer 
System 
Western blotting transfer 
system 
BIO-RAD 
Vortex Genie 2 Vortexer Scientific Industries 
Wallac Victor2 1420 Multilabel 
counter 
Plate reader PerkinElmer Inc 
Water bath model 1003 Water bath GFL 
 
 
 
Table 11. Software used for measurements and analysis 
Product Supplier 
Attune® Cytometric Software V2.1 Thermo Fisher Scientific 
ChemiDoc™XRS System BIO-RAD 
FlowJo® V10 FlowJo 
GraphPad Prism® Version 7 GraphPad Software Inc. 
Image Lab™ Software BIO-RAD 
LightCycler® 96 System Roche 
SnapGene Viewer  Snapgene 
PROSize 3.0 Advanced analytical 
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After interpretation of the results obtained by the huge “human genome project” in 2001, there was 
a cognition that only a small fraction of genetic material, roughly about 1.5%, is coding for proteins81. 
Realizing that most of the non-coding portion of the genome of higher eukaryotes is involved in 
regulation of gene expression and not actually coding for proteins, increased research efforts were 
focused on identifying the key players and their underlying mechanisms of gene regulation.   
A systematic and comprehensive study has revealed that the length of 5’-UTR, which are much 
shorter than 3’-UTR, does not vary greatly among taxa. It ranges between 100 and 200 nucleotides. 
Its composition of G+C nucleotides is higher in warm-blooded vertebrates, where it accounts for 
approximately 60% of the total nucleotides. In general, a G+C content of 5’-UTR is higher compared 
to 3’-UTR.31 
A strategy that affects the translational efficiency42, stability82 of IVT mRNA and their subcellular 
localization83, is the incorporation of 5’-UTR regulatory sequences, especially those that have been 
previously found to modulate these features of endogenous mRNA. In one of the previous studies, 
five different cellular UTRs for enhanced translation and mRNA stability were compared84. Among 
the compared candidates, human cellular CYBA UTR sequences were reported to increase mRNA 
translation without affecting the half-life of recombinant RNA transcripts. The functionality of these 
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regulatory UTRs is embedded not only in their primary sequence but also involves the assembly of 
the secondary structure which is, in turn, recognized by RNA-binding proteins31. As shown in 
experimental studies, moderately stable 5’-UTR secondary structures (ΔG>-30 kcal/mol), directly 
preceding start codon, do not stall the scanning of the 40S ribosomal subunit. If, on the contrary, 
very stable structures are inserted at this strategic position, (ΔG<-30 kcal/mol), inhibitory effects on 
translation initiation have been reported.38 
In the case of endogenous mature mRNA, already transported from the nucleus to the cytoplasm, 
the following event is recognition of the m7G cap structure by the initiation factor eIF4F. This protein 
complex consists of three subunits: the cap-binding protein (eIF4E), ATP-dependent RNA helicase 
(eIF4A) and a subunit that binds to other polyadenylate-binding proteins (eIF4G). Firstly, the helicase 
eIF4A unwinds the RNA, and possibly all secondary structures within, so that the small ribosomal 
subunit (40S) can easily attach to it.85 Poly(A) binding protein bound to the poly(A) tail assists in the 
ribosomal attachment by creating a circular-loop structure together with m7G cap, to facilitate the 
physical interaction with initiation factor eIF4F.86 Subsequently, the ribosome scans the mRNA for the 
first initiation codon (AUG). This ribosomal scanning is the most widely accepted mechanism for 
translation initiation of eukaryotic mRNA (Figure 6). As the initiation takes place at the first AUG 
codon, 40S ribosomal subunit, after attaching to the mRNA, moves along the mRNA and scans it 
forward. The context of nucleotides surrounding start codon AUG actually form a consensus, 
GCCRCCaugG, often called “Kozak consensus”.87 The most conserved nucleotides are positioned at -3 
(purine, usually an A) with respect to the AUG start codon, and at +4 (guanine). These preferred 
nucleotides are conserved in the majority of the 5’-UTR region of animals, plants, and fungi, and may 
modulate recognition of AUG start codon.88 Regulation of gene expression through 5’-UTR is tightly 
controlled, and mutations altering it can have disastrous pathological outcome.45 
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Figure 6.  Scheme of the eukaryotic cap-
dependent translation initiation mechanism.  
The first step of the initiation (on the left) 
involves assembly of 43S ribosomal complex, 
consisting of the 40S ribosomal subunit, eIF2, 
GTP, Met-tRNAi, eIF1A, eIF3, and eIF5. At the 
same time, mRNA is activated by the 
unwinding of 5’-UTR region by eIF4A subunit. 
By positioning a 43S complex at the 5’ cap, a 
48S pre-initiation complex is formed. A 
poly(A) tail, containing PABPs interacts with 
eIF4G1 to circulate the mRNA. An ATP-
dependent scanning process in a 5’ to 3’ 
direction starts until an AUG codon is found. 
Then, codon and anticodon are base-paired 
and Met-tRNAi is incorporating the first 
amino acid of the polypeptide chain, Met. 
Upon AUG recognition, a conformational 
change causes eIF5 to hydrolyze eIF2-GTP, 
thereby releasing Pi and eIF1. Larger 
ribosomal subunit, 60S, joins smaller 48S 
complex mediated by eIF5B and eIF1A, what 
releases eIF2-GDP, eIF3, eIF4 and eIF5. The 
newly composed 80S ribosome is now ready 
for elongation of the polypeptide chain after 
eIF5B hydrolyzed GTP and released eIF1A. 
Figure adapted from Haimov et al, 2015. 89 
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As already mentioned in chapter 1.3, one of the ways to reduce immunogenicity of the IVT mRNA for 
therapeutic purposes is to incorporate modified nucleotides. However, this has been shown to alter 
the secondary structure of the mRNA molecule thereby resulting either in complete loss of 
function79, or reduced binding to pattern recognition receptors77. Having that in mind, the rational 
design of beneficial 5’-UTRs should result in sequences that are not susceptible to secondary 
structure changes due to use of different modifications, and functional in a cell-type independent 
manner. Minimalistic 5’-UTR based mRNA design was combined with the use of chemically modified 
nucleotides with the aim of improving the translational efficiency of the resulting mRNAs. The focus 
was also laid on testing different translation regulators since most previous studies have been 
performed using the traditional Kozak element. Elfakees et al.90 reported that approximately 5% of 
the protein-coding genes with short UTRs harbor a unique translation initiation element (translation 
initiator of short UTRs: TISU). TISU-mediated translation, though cap-dependent, is initiated through 
a non-canonical scanning mechanism.90 The translation is facilitated by eIF1, indicating that it 
interacts with eIF4G1. Upon release of eIF4F, AUG is recognized by the 48S ribosomal subunit40. The 
detachment of the cap complexes enables translation from such short 5’-UTR, at the same time by 
preventing a clash between the eIF4F cap complex and 48S (Figure 7). It is assumed that TISU 
supports translation even under stressed conditions what is supported by their high prevalence 
among genes associated with high energy metabolism and mitochondrial activities.89 
Some of the naturally occurring 5’-UTRs in cellular genes and UTR elements from viruses were used 
as benchmarks.91–93 Besides being cell-type and modification independent, the UTR should ideally 
also work with a broad range of sequences. For this, minimal UTR design was tested with two 
different classes of proteins: intracellular protein (firefly luciferase) and secretory protein (human 
erythropoietin). To test for cell type dependency, experiments were performed in two cell types of 
different tissue origin: human lung alveolar epithelial cell line (A549) and human hepatocellular 
carcinoma cells (HepG2). Finally, the minimal UTR concept was also tested in mice after intravenous 
injection of mRNA-lipid nanoparticles. 
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Figure 7. A schematic view on 
cap-dependent and scanning 
independent translation 
initiation of constructs 
harboring the TISU element. 
When mRNA contains a very 
short 5’-UTR, AUG is located 
in a proximity of cap. Cap-
binding complex recruits pre-
initiation complex and 
recognize AUG, resulting in 
eIF1 displacement and eIF4F 
detachment from the cap. 
Then, AUG is placed at the P-
site. In this model, RNA 
circulation is prevented by the 
release of eIF4F from the cap. 
Figure adapted from Haimov 
et al, 2015. 89 
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4.2.1. Plasmid preparation 
The synthetic 5’-UTR sequences 1-7, as well as reference UTRs, were cloned by a PCR-based strategy. 
The coding sequence for firefly luciferase was amplified from a pGL4.10 plasmid (Promega). For each 
UTR, a specific set of primers was designed. PCR reaction was performed using Pfu DNA polymerase 
(Promega) following the manufacturer’s instructions. Correct PCR products (desired UTR with the 
gene of choice) were cloned into pUC57-Kana vector (GenScript). 
 
4.2.2. Generation of mRNA 
To generate in vitro transcribed mRNA, plasmids were linearized by BstBI digestion and purified by 
chloroform extraction and ethanol precipitation94. Purified linear plasmids were used as a template 
for in vitro transcription. Plasmid templates (0.5 μg/μl) were subjected to in vitro transcription using 
3U/μl T7 RNA polymerase (Thermo Fisher Scientific), with a defined choice of natural and chemically 
modified ribonucleotides (Jena Biosciences). The modification set 1, involving 25% of 5-
methylcytidine and 25% of 2-thiouridine was synthesized as described previously77,95. As for 
modification set 2, instead of 5-methylcytidine (25%) and 2-thiouridine (25%), 5-iodouridine (35%) 
and 5-iodocytidine (7.5%) were used. The complete IVT-mix was incubated at 37°C for 2h. Afterward, 
0.01 U/μl DNase I (Thermo Fisher) was added for an additional 45 min at 37°C to remove the plasmid 
DNA template. RNA was precipitated with ammonium acetate at a final concentration of 2.5 mM, 
followed by two washing steps with 70% ethanol. The pellet was re-suspended in aqua ad 
injectabilia. A C1-m7G cap structure was added enzymatically to the 5' end of the transcript using 
Vaccinia Virus Capping Enzyme (NEB) following manufacturer’s instructions. The 3' end of the 
transcript was subjected to enzymatic polyadenylation of ~ 120 nucleotides, using E. coli poly(A) 
Polymerase (NEB). RNA quality and concentration were measured spectrophotometrically on a 
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NanoDrop2000C (Thermo Fisher Scientific). Its correct size and purity were determined via 
automated capillary electrophoresis (Fragment Analyzer, Advanced Analytical). 
 
4.2.3. Cell culture 
A549 (ACC-107) and HepG2 (ACC-180) cells were purchased from DSMZ. They were cultured in 
Minimum Essential Media (MEM) with Glutamax (Gibco/Life Technologies) and RPMI 1640 plus 
GlutaMAX (Gibco/Life Technologies) respectively. Both media were supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Gibco/Life Technologies) and 1% penicillin/streptomycin 
(Gibco/Life Technologies). Cells were cultured in a humidified 5% CO2 incubator at 37°C.  
 
4.2.4. In vitro transfection  
Both cell lines, A549 and HepG2 were transfected with two different doses of mRNA (125 ng/well 
and 250 ng/well). A549 and HepG2 cells were seeded at the density of 2x104 cells/well and 4x104 
cells/well respectively in a 96 well plate. 24 hours post-seeding, cells were transfected using the 
commercial transfection reagent Lipofectamine®2000 (Thermo Fischer Scientific). Complexes were 
prepared at a ratio of 2 μl Lipofectamine®2000 per 1 μg mRNA. The mRNA was diluted 1:20 in water, 
and Lipofectamine®2000 1:10 separately in a serum-free MEM. mRNA was added to the 
Lipofectamine®2000 solution followed by 20 min incubation time at RT. The concentration of the 
final mRNA/Lipofectamine®2000 solution was 25 ng/μl, and a serial dilution 1:2 was performed. 10 μl 
of the complex solution was added to the cells and cells were incubated for 24 and 48 h, respectively. 
For every mRNA construct, replicates of three or six were prepared.  
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4.2.5. Firefly Luciferase Assay 
For detection of firefly luciferase activity, cells were lysed for 30 min at RT in lysis buffer (25 mM Tris-
HCl, 0.1% TritonX-100, pH 7.4). Luciferase assay was performed as described previously96–98. Photon 
luminescence emission was measured for 5 s using Tecan InfiniteR 200 PRO.  
 
4.2.6. Rabbit reticulocyte lysate, the cell-free translation system 
Nuclease treated rabbit reticulocyte lysate (Promega) were used for investigating translation from 
luciferase-encoded RNA transcripts. The experiment was set up following the manufacturer’s 
procedure. The reaction was analyzed after luciferase buffer application, by measuring photon 
luminescence emission for 5 s using Tecan InfiniteR 200 PRO.  
 
4.2.7. Lipid formulation 
For in vivo experiments, mRNA was formulated in lipid nanoparticles (LNPs) as previously described.99 
 
4.2.8. In vivo studies 
For in vivo studies, Balb/c mice (Charles River Laboratories) at the age of six to eight weeks, were 
used. All animal experiments were carried out according to the guidelines of the German law of 
protection of animal life and reviewed by the local ethics committee. Mice were injected 
intravenously with 20 μg LNP formulated mRNA. In vivo imaging of luciferase expression was 
performed at 6 h post-delivery using an IVIS Lumina XR Imaging System (Caliper Life Sciences) and 
organs were harvested and analyzed for ex vivo luciferase measurements as described previously99.  
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4.2.9. Enzyme-linked immunosorbent assay 
Quantification of hEPO protein was performed using human Erythropoietin Quanktine IVD ELISA kit 
(R&D Systems) following manufacturer’s instructions. 
 
4.2.10. Statistical analysis 
Each experiment was performed with at least three technical replicates per sample. Results are 
shown as means ±SD unless otherwise stated. Statistical analysis was performed using GraphPad 
Prism software (version 6). Data were tested for normal distribution using D’Agostino-Pearson 
omnibus normality test. Multiple comparisons were conducted by two-way ANOVA, followed by 
Sidak’s test (pairwise comparison) or Dunnett’s test (many-to-one comparison). A p-value ≤ 0.05 was 
considered statistically significant. 
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Upstream of the gene of interest, recombinant DNA sequences making short synthetic 5’-UTRs were 
cloned into the plasmid. Their sequence and position of each base relative to the start codon is listed 
in Table 12.  
 
Table 12. Sequences of synthetic 5’-UTR with annotation of each nucleotide position.  
Each sequence comprised of the T7 promoter (T7), the desired 5’-UTR and a luciferase coding sequence. Listed are the 
respective sequences, each starting with a GGG as a transcription-starting site and ending with an ATG, a start codon. The 
upper row of numbers indicates the position of those nucleotides with respect to the transcription start site, as GGG is the 
first triplet transcribed into mRNA. The lower row of numbers indicates coordinates of nucleotides with respect to the start 
codon (ATG). 
minimal 
5’-UTR  
Promoter34,35 
Transcription start 
site34,35 → 
Extra 
nt 
Kozak consensus87 
Start 
codon  
← 
  1 2 3 4 5 6 7 8     
   -6 -5 -4 -3 -2 -1 1 2 3 
UTR1 T7 G G G A G A   G C C A C C A T G 
UTR2 T7 G G G A G A C  G C C A C C A T G 
UTR3 T7 G G G A G A C T G C C A C C A T G 
UTR4 T7 G G G A G A C A G C C A C C A T G 
UTR5 T7 G G G A G A C C G C C A C C A T G 
UTR6 T7 G G G A G A C G G C C A C C A T G 
UTR7 T7 G G G A G A C T G C C A A G A T G 
 
All sequences combined T7 promoter (TAATACGACTCACTATA) with Kozak consensus element 
(GCCACC), forming very short 5’-UTR upstream of the start codon ATG (minimal UTR; Table 12). The 
last 6 nucleotides of the T7 promoter, directly downstream of the TATA box, are needed to ensure 
the homogeneity of the 5’ end, and to enhance the yields of in vitro transcribed mRNA100–104. 
Comprising only these necessary elements for transcription and translation, a short synthetic 5’-UTR 
was formed (UTR1), with the sequence: GGGAGAGCCACC. A UTR2 sequence harbored an additional C 
nucleotide at base position +6 in mRNA, inserted between the T7 promoter and Kozak consensus. 
With this insertion, the G at position +5 aligned with -9 position (with respect to start codon), 
thereby resulting in complete Kozak consensus (GCCGCCACC)105.  
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4.3.1. Effect of spacer nucleotides between the T7 promoter and Kozak element 
The first set of experiments were designed to compare translation efficiencies of UTR1 and UTR2 
containing luciferase-coding transcripts. The efficiency of in vitro transcribed transcripts, using either 
unmodified or modified sets of nucleotides (modification 1, modification 2) was tested in two 
different cell lines, A549 and HepG2. As seen from Figure 8, a very minimal synthetic 5’-UTR, namely 
UTR1, expressed less luciferase than its counterpart harboring an extra nucleotide of C. A significant 
increase of protein levels for UTR2 was observed in both cell types and time points (24h and 48h). 
Since UTR2 performed better, its minimalistic design was used in all the following constructs. 
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Figure 8. Luciferase activity in protein lysates from A549 and HepG2 cells transfected with minimal UTR1 and minimal UTR2 
(Table 1) containing Luc mRNAs.  
Luciferase activity was measured 24h (a, c, e) and 48h (b, d, f) post-transfection. Statistical significance was assessed by 2-
way ANOVA test with p-values: *p≤0.05, **p≤0.01, ***p≤0.001, n=6.  
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Using UTR2 as a template, the assortment of short synthetic 5’-UTR was expanded by increasing the 
distance between the T7 promoter and Kozak consensus. The distance was increased by only 1 extra 
nucleotide, and the choice involved all 4 possibilities: T, A, C or G at the -7 position. This way, four 
new constructs were created, namely UTR3-6 (Table 12). In the subsequent experiment, 5’-UTR from 
human alpha-globin was inserted into luciferase-encoding mRNA. Since this combination of 5’-UTR 
was shown to increase protein translation in cellular systems39, it was used as a benchmark for the 
short synthetic UTRs. As for previous experiment (Figure 8), all IVT mRNA constructs were produced 
in both, unmodified and modified forms and they were further used for A549 cell transfection. With 
the construct harboring an extra T between the T7 promoter and Kozak consensus (UTR3), the 
highest protein expression was observed, compared to other three constructs with the different 
extra single nucleotide at position -7 (UTR4-6). This translation enhancing effect was either 
comparable to or better than the effect seen with human alpha-globin 5’-UTR containing mRNA 
(refUTR1). Similar trends were observed at both time points (Figure 9).  
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Figure 9. Luciferase activity in protein lysates from A549 cells transfected with different UTRs containing Luc mRNA. 
Luciferase activity was measured 24h (a, c, e) and 48h (b, d, f) post-transfection. Statistical significance was assessed by 2-
way ANOVA test, comparing each mean of the column with the minimal UTR3. P-values indicate: *p≤0.05, **p≤0.01, 
***p≤0.001, n=6. 
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4.3.2. Effect of translation regulator 
From published literature, it can be expected that the choice of translation regulator will influence 
mRNA translation. Due to their specific, conserved nucleotide sequence, subsequent experiments 
were designed to investigate their effect on translation as influenced by the choice of nucleotide 
modifications and cell types. TISU element was previously found to be a specific translation regulator 
for sequences with very short 5’-UTRs106. As UTR3 resulted in highest expression (comparable or 
better than benchmark refUTR1), minimal UTR3 was chosen as a template for creating minimal UTR7 
(Table 12). In UTR7, Kozak element is substituted with TISU element, and as a gene of interest, 
luciferase was further used. Both cell lines, A549 and HepG2 were transfected with those mRNAs, 
including unmodified and modification sets 1-2. The functionality of the regulator of translation was 
shown to be affected upon incorporation of modified nucleotides during in vitro transcription in both 
cell lines. In the case of transfection with unmodified IVT mRNA, luciferase expression levels were 
comparable. A significantly higher luciferase expression was observed in construct furnished with the 
TISU element (UTR7) while using IVT modification set 1 mRNA when compared to the construct with 
Kozak element (Figure 10). However, when observing expression from modification set 2, an 
opposite trend was observed. These observations were consistent at both time points. 
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Figure 10. Luciferase activity in protein lysates from A549 and HepG2 cells transfected with either Kozak (UTR3) or TISU 
(UTR7) element within Luc mRNA. 
Luciferase activity was measured 24h (a, c, e) and 48h (b, d, f) post-transfection. Statistical significance was assessed by 2-
way ANOVA test. P-values indicate ns>0.05, *p≤0.05, **p≤0.01, ***p≤0.001, n=6.  
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a                                                               b                                                         c 
4.3.3. In vivo comparison of different Luciferase coding mRNA constructs 
As minimal UTR3 showed potential supported by results with comparable expression levels to those 
from commonly used human alpha-globin 5’-UTR and UTR7, it was selected as a lead candidate to be 
tested in vivo. Apart from the human alpha-globin UTR, luciferase construct proposed by Guild et al91, 
composed of 5’-UTR from the human CMV enhancer and 3’-UTR from the human growth hormone 
(refUTR2), was selected as a second benchmark. Many other short UTRs have been published 
previously39,91,92, which were tested as additional benchmarks for the short synthetic UTR constructs 
from the current study. For this, minimal UTR7 was compared to, the additional reference UTRs 
(refUTR-5). Their sequences are listed in Table 13. These UTR sequences were previously reported to 
enhance protein expression91. Listed mRNAs were transcribed incorporating chemically modified 
nucleotides as defined by set 1 and afterward formulated in a previously described lipid 
formulation99. Experiments were performed in 6-8 weeks old Balb/c mice by intravenously injecting 
20 µg LNPs per mouse. Bioluminescence imaging was performed 6h post-injection and luciferase 
expression was as photons/sec/cm2/sr. As IV delivery of LNPs results in maximal expression in the 
liver, luciferase expression in isolated organs (liver and spleen) was also measured ex vivo. Similar to 
the results obtained in vitro, minimal UTR3 was as effective as the benchmark (refUTR1). Comparing 
minimal UTR7 harboring TISU translation regulator to Kozak containing counterpart (minimal UTR3), 
the levels of expression were significantly higher. The second benchmark, refUTR2, was significantly 
lower than the minimal UTR7 in liver and spleen. Similar trends were observed irrespective of the 
imaging (whole animal in vivo vs. organs ex vivo) (Figure 11).  
 
Figure 11. Luciferase expression in mice injected with 20µg of different luciferase coding RNAs produced using 
modification1. 
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Luciferase expression was measured at 6 h post i.v. injection using In Vivo Imager (animal - a). Liver (b) and spleen (c) were 
harvested post measurement for ex vivo luciferase measurements. 
 
4.3.4. Comparison of short synthetic UTRs to naturally occurring viral and human UTRs 
Many other short UTRs have been published previously39,91,92, which were tested as additional 
benchmarks for the short synthetic UTR constructs from the current study. For this, minimal UTR7 
was compared to, the additional reference UTRs (refUTR3-5). Their sequences are listed in Table 13.  
 
Table 13. Sequences of 5' and 3'-UTRs references used in the present study.  
Listed are five 5’-UTR sequences that were used as benchmarks, with their gene source and literature reference. 
Reference 
UTR 
5’-UTR sequence 5’-UTR source 3'-UTR sequence 
5’-UTR 
source 
Reference 
refUTR1 
GGGAGACTCTTCTGGTCCC
CACAGACTCAGAGAGAAC 
hαg / / 39 
refUTR2 
GGAGACGCCATCCACGCT
GTTTTGACCTCCATAGAAG
ACACCGGGACCGATCCAG
CCTCCGCGGCCGGGAACG
GTGCATTGGAACGCGGAT
TCCCCGTGCCAAGAGTGA
CTCACCGTCCTTGACACG 
human 
cytomegalovirus 
(hCMV) 
CGGGTGGCATCCCTGT
GACCCCTCCCCAGTGC
CTCTCCTGGCCCTGGA
AGTTGCCACTCCAGTG
CCCACCAGCCTTGTCC
TAATAAAATTAAGTTG
CATC 
human 
growth 
hormone 
(hGH) 
91 
refUTR3 
GGGAGACAAAAAAAAAAA
AAAAAAAAA 
orthopoxvirus / / 
92 
refUTR4 
GGGAGACCATATTGAAGA
GACAGAGTGATATATAAA
ACTGCTAA 
deep sequencing 
of human genome 
/ / 
93 
refUTR5 GGGAGACAAAACTGCTAA 
deep sequencing 
of human genome 
/ / 
93 
 
In vitro transfection was done in A549 cells, with above-mentioned IVT mRNAs. Again, both 
unmodified and chemically modified transcripts were tested. Synthetic UTR7 achieved comparable 
expression to refUTR3, regardless of the modification used (Figure 12). Higher expression with 
minimal UTR7 was achieved when compared to refUTR4 (unmodified, modification 2) and reference 
UTR5 (modification 2) after 24h, but the effect diminished after 48h. 
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Figure 12. Luciferase activity in protein lysates from A549 cells transfected with different short transcription regulator 
elements.  
Luciferase activity was measured 24h (a, c, e) and 48h (b, d, f) post-transfection. Statistical significance was assessed by 2-
way ANOVA test. P-values indicate: ns>0.05, **p≤0.01, n=4. 
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To rule out the possibility that different UTR sequences were affecting critical mRNA attributes (e.g. 
capping, a proportion of full-length transcripts etc.) or differential transfection efficiencies 
contributing to the above-observed differences, translation experiment was carried out in nuclease-
treated rabbit reticulocyte lysates. Equal amounts of IVT mRNA of minimal UTR7 and refUTR3-7 were 
applied to the cell lysates. For each mRNA type (unmodified, modification 1 and modification 2), a 
comparable level of luciferase expression was observed among the different UTRs (Figure 13). These 
results confirm that the observed differences in translation efficiency can be attributed to the cellular 
performance of particular UTR elements. 
 
Figure 13. Luciferase activity in a cell-free translation system of rabbit reticulocyte lysates with different short transcription 
regulator elements.  
Luciferase activity was measured 60 min post-transfection.  
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4.3.5. A sequence-independent function of minimal UTR7 
To test if results observed with luciferase, an intracellular protein, were transferable to another class 
of protein e.g. secreted protein, additional constructs were made with UTR7 and human EPO. As a 
reference, refUTR2 was combined with the EPO coding sequence. mRNA was in vitro transcribed 
using modified nucleotides as defined by set 1. A549 and HepG2 cells were transfected, and EPO 
expression was quantified via ELISA at 24h post-transfection. Expression of EPO in A549 cells 
revealed that UTR7-containing mRNA produced more protein than refUTR2 (Figure 14). Similar 
results were obtained in HepG2 cells as well, although the difference was not statistically significant.  
 
 
Figure 14. Quantification of secreted human erythropoietin protein levels as measured via ELISA in A549 (a) and HepG2 (b) 
cell supernatants at 24 hours post-transfection.  
Values represent mean ± SD of 3 replicates. Statistical significance was assessed by 1-way ANOVA test with p-values: 
ns>0.05, *p≤0.05. UT = untransfected. 
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The goal of this study was to design minimalistic 5’-UTRs and compare their functionality to naturally 
occurring 5’-UTRs with respect to their effect of protein translation after mRNA delivery to the cells. 
Synthetic minimal UTRs were comprised only of elements necessary for in vitro transcription (T7 
promoter) and translation in the cells (AUG start codon), with several different versions of 
connecting nucleotides between the elements.  
A T7 promoter is recognized by a phage T7 polymerase, which catalyzes the formation of RNA in the 
5’ → 3’ direction. A T7 polymerase is a convenient tool based on its low error rate and extremely 
promoter-specific expression107. In the earlier studies, it has been proposed that T7 promoter 
contains two functional domains: the binding region, from -17 to -5, and the catalytic domain 
downstream of -5 position103,104. In the study by Imburgio et al, it was reported that the position of 
nucleotides in the binding region of mRNA affects the promoter recognition and, therefore, initiation 
of the reaction.102 A selection of promoter variants was designed, and it was found that any base 
substitution at position +1 to +6 from the wild-type sequence (GGGAGA) negatively affected the 
strength of promotor. Based on this finding, short synthetic minimal 5’-UTRs in the current study 
were designed with respect to conserved T7 promoter elements. 
The major factor determining the ATG recognized as the start codon is the Kozak consensus 
sequence, in vertebrates determined as (GCC)GCCRCCATGG, where R is a purine (A or G).108–111 The 
data were compiled by Kozak et al, from 699 vertebrate mRNAs, where 33% contained a G at the -9 
position. At the position -7, 37% contained a C.87 The experimental manipulation of the nucleotides 
within a certain position in the sequence revealed that some nucleotide positions are more 
important than the others are. This was especially true for -3 (R) and +4 (G) positions, where their 
mismatch caused poor gene expression.112 In line with these details, minimal UTR2 actually followed 
the perfect consensus Kozak rule (GCCGCCACC), by fusing T7 promoter and Kozak element, with an 
extra C in between. By inserting an additional C nucleotide at position -7 (seven nucleotides 
upstream from the ATG codon), a G residue previously placed at the -8 position (in minimal UTR1) is 
DESIGN OF SHORT SYNTHETIC 5’-UTR SEQUENCES 
 
38 
shifted to the -9 position (in minimal UTR2), with respect to the start codon. Therefore, bringing in an 
extra C into the very minimal UTR1 sequence, significantly increased protein expression in cells from 
delivered mRNA.  
Further experiments, where each possible nucleotide was fused into the sequence at the base 
position +8 in the mRNA among the elements, showed that particularity an extra T (minimal UTR3) 
enhanced protein expression. This observation was independent of the use of modified or 
unmodified nucleotides in the mRNA. 
The potential of minimal UTR3 was later compared to 5’-UTR from human alpha-globin gene, which 
has been shown to affect mRNA stability and its translation. As an example, in a study by Schrom et 
al113, incorporation of the 5’-UTR from human alpha-globin prior to the gene encoding human 
angiotensin-converting enzyme part 2 (hACE2), increased enzyme translation and mRNA stability, 
when compared to naturally occurring hACE2 5’-UTR, or even the CYBA UTR.84,113 Moreover, 5’-UTR 
from human alpha-globin has been reported to have higher translation efficiency compared to beta-
globin 5’-UTR39. The reference sequence for human alpha-globin from the NCBI database 
(NM_000517.4) was used as a 5’-UTR, but only from positions 31 to 60, although its full length is 66 
nucleotides.114 The reason for selecting this section is that nucleotides prior to those are not 
transcribed into the mRNA. In our constructs, nucleotides from 55 to 60 in the wild-type 5’-UTR from 
human alpha-globin (GGGAGA) were replaced by standard Kozak sequence (GCCACC).  
The performance of different UTRs was also affected by the choice of nucleotide modifications used, 
what was especially seen in the case of the benchmark human alpha-globin 5’-UTR (refuUTR1) when 
used with modification 2. The functionality of refUTR1 in luciferase expression was reduced, what 
was especially seen at 48h post-transfection. However, while using it either with the unmodified or 
with modification 1 mRNA, no significant difference in expression was observed. These findings 
highlight the sensitivity of natural UTR sequences to the choice of modification used in mRNA 
production. Some of the chemically modified nucleotides might alter the secondary structure of UTR 
region in such a manner that it may lose its functionality. This, in turn, might result in loss of function 
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and, therefore, reduced translation.79,84 An example of such an impairment of the 5’ element 
function was shown by Thess et al, 2015. By the incorporation of pseudouridine, IRES element 
completely lost its function as a recruiter of translation initiation in a cap-independent manner.79  
As some of the previous studies imply, the minimal length of 5’-UTR to ensure proper binding of the 
ribosome and therefore translation initiation at the start codon is 32 nucleotides. Having fewer 
nucleotides than that initiates the translation at some of the downstream ATG instead of the first 
start codon111,115. Considering that the short synthetic UTRs in the current study consisted of a 
maximum of 15 nucleotides, TISU element was tested as a translational regulator in a direct 
comparison with Kozak element to support the translation from these short 5’-UTRs. Moreover, a 
majority of previous studies involving usage of chemically modified nucleotides in mRNA transcripts 
did not investigate its effect on any other translation regulator but Kozak element.72,73,77,79,84,95,113,116 
Defined as a translation initiator of short UTRs, TISU was first discovered in the 5% of short 5’-UTRs of 
non-coding human gene region.106 With a unique sequence of AAGAUGG (minimal UTR7), it is 
distinguished from the Kozak sequence RCCAUGG (minimal UTR3). In the direct side-by-side 
comparison of these two translation regulators, significant translation differences were observed 
when using modification 1 containing mRNA. Minimal UTR7 mRNA translated more efficiently at 24h 
and 48h post-transfection, what can be directly contributed to the TISU element since this is the only 
difference between the two sequences. Since both modification sets (modification 1 and 2) contain 
modified C (5-methylcytidine in modification 1 and 5-iodocytidine in modification 2), it is possible 
that either all or some of the Cs preceding the ATG codon in the Kozak context (ACCATG) get 
modified. In the case of TISU-containing sequences, this scenario is theoretically not possible since 
there is no C located in the three bases upstream from ATG (AAGATG). This could be the explanation 
of how specific chemical modification(s) could alter and affect the performance of regulatory 
elements, whether it be UTRs or translation regulators.  
Due to the encouraging results obtained in vitro, the potential of minimal UTR3 and UTR7 luciferase-
encoding constructs was also confirmed in vivo in mice. The refUTR2 from a previous study91 was 
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used as an additional benchmark in these in vivo experiments. Similar to the in vitro results, minimal 
UTR7 resulted in highest translation efficiency compared to minimal UTR3 and refUTR2. As the same 
trend was observed in liver and spleen, the activity of minimal UTRs is likely to be cell-type 
independent.  
Data with human EPO-mRNA in A549 and HepG2 cells confirm that translation-enhancing effect of 
minimal UTR7 is the sequence- and cell-type- independent. Minimal UTR2 had a positive impact on 
translation compared to CYBA 5’-UTR84 or natural 5’-UTR from hACE2113 in previous studies, what 
confirms a conceptual advantage of minimalistic UTRs (minimal UTR7 is 113 nucleotides shorter than 
refUTR2). 
Encouraged by the in vitro and in vivo results, minimal UTR7 was further benchmarked to several 
other naturally occurring 5’-UTRs. A short homopolymeric stretch of 20 adenosines at the 5’-end is a 
characteristic of orthopoxviruses, enabling them to repress mRNA decay (refUTR3)92. Based on the 
metagenomics study of the human genome that revealed a 37-nucleotide long conserved sequence, 
refUTR4 was created. The sequence was reported to promote expression in a cytoplasmic expression 
system that is based on Vaccinia virus (VACV)93. Based on the length of a functional promoter in the 
reported system93, two new constructs were designed: refUTR4 containing 37 nucleotides of 
promotor with translation enhancer, and refUTR5 containing only the translation enhancer. In a 
direct comparison, minimal UTR7 was either comparable to or better than these new benchmarks 
(refUTR3-5).  
Although the mechanism of the performance of short synthetic 5’-UTRs was not investigated, one of 
the underlying factors for their expression effect is unlikeliness of forming secondary structures, 
either themselves or with downstream sequences. That also makes them less susceptible to the 
changes upon chemical modification of nucleotides. Synthetic, minimal but effective UTRs as such 
will reduce the amount of mRNA to achieve therapeutic efficiency, at the same time reducing the 
costs of such therapies.  
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It could be shown that synthetic sequences, designed on a rational sequence-design approach, 
outperform some of the most widely used 5’-UTRs, both in vitro and in vivo. Based on these data, 
minimal UTR3 and minimal UTR7 present themselves as promising candidates for the future 
development and use in mRNA-based therapeutics. None of these two sequences had any negative 
effects on RNA yield during in vitro transcription. Translation of these UTR containing mRNAs was a 
sequence- and cell-type- independent and either comparable or better than some of the widely used 
UTRs. Due to their short length, UTR3 and UTR7 are less prone to the structural change upon 
incorporation of chemically modified nucleotides, or cell- and target sequence- specific effects.
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A distinct feature of the cellular mRNAs is a long chain of adenosines, located at the 3’-end of the 
molecule. Regardless of the protein that it encodes for or the tissue where it is expressed, it is a 
common structural feature of all cellular mRNAs, with some exceptions, e.g. histones. In the nucleus 
of the cell, shortly after the mRNA is synthesized by transcription, it undergoes several processes 
altering both ends, known as RNA processing. The posttranscriptional modifications are essential for 
a multitude of processes starting from export from the nucleus to successful translation including 
mRNA stability. One of such processes, occurring at the 3’-end is polyadenylation, a two-step process 
of adding poly(A) tail to the nascent molecule downstream of the gene-encoded polyadenylation 
signal (AATAAA). However, the poly(A) tail is not encoded in the genes; it is an end-product of a 
polyadenylation reaction, which follows site-specific cleavage117. It varies in length among 
eukaryotes, ranging from 90 adenosines in yeast to ~250 in mammals.118,119 
Poly(A) tail also plays a role in mRNA maturation, by making it more stable and preventing 
degradation by nucleases28; it is an essential part for the nuclear export of mature mRNA27; it initiates 
the translation by the formation of the closed-loop structure. A formation of the closed-loop state is 
initiated by association of poly(A) binding proteins (PABP) with the poly(A) tail, which then interacts 
with the eIF4G of the translation initiation complex, attached to the cap 118,120 (Figure 15). Sachs et al 
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have shown that such a formation promotes 40S ribosomal recruitment towards mRNA, resulting in 
enhancement of translation in S.cerevisiae.29 
Although there were many debates on whether the P-bodies play a role in mRNA decay or storage, 
recent findings show that these small cytoplasmic granules are the place of continued storage of 
mRNAs. An important parameter for the storage is the size of the poly(A) tail; the data suggest that 
there is a tendency towards shorter poly(A) tails, but there is no confirmation yet.121 
 
 
 
Figure 15. Closed-loop structure of the mRNA. It is initiated by the interactions between eIF4E, a cap-binding protein, and 
PABP, a poly(A)-binding protein through eIF4G1 as a linker.  
Figure adapted from “An emerging interest in RNA world” [Internet]. MBL Life Sci. 122 
 
mRNA molecules intended for therapeutic purposes of protein synthesis are generated by in vitro 
transcription. Considering the procedure, the poly(A) tail can be either added enzymatically by 
poly(A) polymerase from E.coli in a post-transcriptional step or encoded already in the DNA template 
(plasmid or PCR template). Both methods suffer from certain limitation. Enzymatic addition of the 
poly(A) tail to the in vitro transcribed mRNA ensures sufficiently long poly(A) tails123,124, but the 
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product is heterogeneous as the same length of the poly(A) for all mRNA molecules cannot be 
ensured; i.e. the length remains difficult to optimize. This means, that the end product is actually a 
heterogeneous mixture of different length of the poly(A) tails, which could in turn cause problems 
meeting the FDA regulatory requirements.58 mRNA is susceptible to alkaline hydrolysis and as poly(A) 
polymerase requires alkaline conditions (pH > 7.5) to be fully functional, post-polyadenylated mRNAs 
are often of lower quality when compared to their controls without polyadenylation.125 
Thus, template-encoded poly(A) is a preferred way of adding a poly(A) tail to the mRNA over 
enzymatic post-polyadenylation of mRNA. Reproducibility of the defined poly(A) length, which in turn 
results in a homogeneous product are some of the advantages of this approach.126 Moreover, the 
procedure involves fewer steps of RNA production than enzymatic post-polyadenylation, reducing 
the costs of production. 
As for the small-scale mRNA production, a PCR-based approach offers advantages such as high 
throughput. However, its high production costs and the risk of mutagenesis during PCR amplification 
that each polymerase carries, restrict its application for large-scale mRNA production for pre-clinical 
and clinical applications. 
Considering large-scale production of the DNA template, a plasmid-based approach is a preferred 
way, due to its ease of scalability, and a well-established procedure that can be implemented under 
good manufacturing practice (GMP) conditions. The risk of mutations in the coding sequence is also 
lower compared to a PCR approach. However, encoding long homopolymeric stretches, such as 
poly(A), into the plasmid DNA causes unpredictable recombination during the bacterial amplification 
of the plasmid DNA.127 In such cases, the poly(A) encoding sequence is shortened over time127, what 
was reported in previous studies. When encoded poly(A) tail sequence was 70 nucleotides long, its 
length remained the same during bacterial amplification.127 After increasing its length to at least 100 
nucleotides, the spontaneous deletion mutants started appearing during the plasmid 
amplification.128 Longer poly(A) tails, comprising 150 nucleotides were so unstable that no positive 
clones could be selected.127 
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Instability of poly(A) in circular plasmids led to the development of the linear plasmid-based system, 
namely pEVL. Such vectors offer the stability of the homopolymeric sequences during the cloning 
procedures and stretches up to 500 base pairs have been successfully clones127. Such linear plasmid-
based system is commercially available as BigEasy® v2.0 Linear Cloning System (Lucigen), but it is a 
relatively large (>12 kb), very low copy vector and therefore not suitable for a large-scale production. 
Regardless of its large size, it offers only a limited choice of restriction sites; either SmaI or NotI 
which limit the cloning/linearization choices 
An ideal solution, addressing the limitations mentioned by each of the above-described approaches 
for adding a stable, well-defined and homogeneous poly(A) sequence in the mRNA, would be to have 
a template-encoded poly(A) tail in the plasmid, which is not undergoing recombination during the 
plasmid amplification in bacteria. A poly(A) tail encoded in such a way would be able to deliver 
templates for in vitro transcribed mRNA production on a large-scale.  
The current study aimed at investigation of segmented poly(A) tail and its effect on bacterial 
recombination during a high-copy plasmid amplification in E.coli. As a starting point, the most widely 
used poly(A) tail of 120 As in length (poly(A)120) was used. To achieve the segmentation effect, but 
also taking note of the functional PABP footprint, the length of 120 As in total was split into either 2 
or 3 segments of 60A’s (poly(A)2x60) or, 40A’s (poly(A)3x40) respectively. Earlier it was shown that PABP 
requires a minimum of 12 As to functionally bind to the poly(A) tail, but a single PABP molecule is not 
sufficient to successfully promote translation.128 However, if oligomers of PABP are formed, they 
occupy approx. 27-30 nucleotides in a repetitive manner of the same poly(A) stretch.129–131 In line 
with these publications, constructs were designed such that at least one oligomeric stretch of PABP 
can bind to each segment of the poly(A) tail. All variations of the poly(A) segmentation were 
compared to poly(A)120, as it was shown to support the high expression of in vitro transcribed 
mRNA.126,132 Initial read out for comparison was the recombination rate of the plasmid in E.coli 
among the constructs. From the selected positive clones, IVT mRNA was produced and transfected 
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into A549, HEK293 and 16HBE14o- cells: both translation efficiency and mRNA half-life 
measurements were made at different time points post-transfection.   
It could be shown that segmented poly(A) significantly reduces recombination of plasmids in E.coli 
without negatively affecting mRNA half-life or translation efficiency. 
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5.2.1. Plasmid preparation 
The synthetic poly(A) sequences were introduced to the vector backbone either as annealed 
complementary oligonucleotides or fragments created by PCR (Table 1). For sequences comprising of 
2x60, 3x40 and ACH, specific sets of complementary oligonucleotides were synthesized and 
annealed. The synthetic poly(A) fragments of A120, 2x60_1, 2x60_12 and 2x60_24 were created by 
PCR.  
Annealing of complementary oligonucleotides was performed as follows: 100 µM of each 
oligonucleotide were mixed with 40 µl annealing buffer (10 mM Tris HCl, 50 mM NaCl, 1 mM EDTA, 
pH 7.5) and incubated for 5 min at 95°C. Subsequently, the mixture was let to cool down to room 
temperature before proceeding with restriction digestion (BglII-BstBI). 
For the high performance of PCR reaction, Phusion High-fidelity PCR master mix (Thermo Fisher 
Scientific) was used. To the mastermix, which contains 2x Phusion DNA Polymerase, nucleotides and 
optimized reaction buffer including MgCl2, 0.5 µM of forward and reverse primer, 3% DMSO and 1 ng 
of template DNA were added to the reaction. The total reaction volume of 25 µl was initially 
denatured at 98°C for 30 sec, following by 30 cycles at 98°C for 10 sec, annealing at 72°C for 30 sec 
and extension at 72°C for 30 sec/kb. The final extension was performed at 72°C for 10 min. The size 
of the PCR product was confirmed on 1% agarose gel and the desired band was purified using 
NucleoSpin Gel and PCR clean-up kit (Macherey Nagel). Purified PCR product was digested with NheI-
BstBI and stored at -20°C until further use. 
Digested products of annealed oligonucleotides and PCR products were cloned into accordingly 
digested pUC57-Kana vector (GenScript) containing the desired coding sequences (firefly luciferase, 
d2EGFP, human EPO and human CFTR).  
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Table 14. Segmented poly(A) sequences and their corresponding cloning strategy using either PCR primer sets or 
oligonucleotides. 
 
Construct Strategy PCR primer forward / Oligo I PCR primer reverse / Oligo II 
2x60_6 Oligonucleotides GTGACTAGATCTAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAATGCATAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAATTCGAAGTGACT 
AGTCACTTCGAATTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TATGCATTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAGATC
TAGTCAC 
3x40_6 Oligonucleotides GTGACTAGATCTAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAATGCATAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAT
ATCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAATTCGAAGTGACT 
AGTCACTTCGAATTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTGATATCTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTATGCATTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TAGATCTAGTCAC 
A120 PCR GTGACTGCTAGCTAATACGACTCACTATAGGGAG AGTCACTTCGAATTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTAGATCTTTAC
ACGGCGATCTTGCCGCCCTTC 
ACH79 Oligonucleotides AGATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAATGCATCCCCCCCCCCCCCCCCCCCCCCCCCCCC
CCCAAAGGCTCTTTTCAGAGCCACCAGAATTCTTC
GAAGTGACT 
AGTCACTTCGAAGAATTCTGGTGGCTCTGAAA
AGAGCCTTTGGGGGGGGGGGGGGGGGGGG
GGGGGGGGGGGATGCATTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTAGATCT 
2x60_C PCR GTGACTGCTAGCTAATACGACTCACTATAGGGAG AGTCACTTCGAATTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTAGATCTTTA
CACGGCGATCTTGCCGCCCTTC 
2x60_G PCR GTGACTGCTAGCTAATACGACTCACTATAGGGAG AGTCACTTCGAATTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTAGATCTTTA
CACGGCGATCTTGCCGCCCTTC 
2x60_T PCR GTGACTGCTAGCTAATACGACTCACTATAGGGAG AGTCACTTCGAATTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTAGATCTTTA
CACGGCGATCTTGCCGCCCTTC 
2x60_12nt PCR GTGACTGCTAGCTAATACGACTCACTATAGGGAG AGTCACTTCGAATTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TCCTCTAATGGCGTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTAGATCTTTACACGGCGATCTTGCCGCCCTTC 
2x60_24nt PCR GTGACTGCTAGCTAATACGACTCACTATAGGGAG AGTCACTTCGAATTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TAGATGCGGACACAATCAGGGGTTGTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTAGATCTTTACACGGCGA
TCTTGCCGCCCTTC 
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5.2.2. Generation of mRNA 
To generate in vitro transcribed mRNA, plasmids were linearized by BstBI (Thermo Fisher Scientific) 
digestion and purified by chloroform extraction and ethanol precipitation. Purified linear plasmids 
were used as a template for in vitro transcription. Plasmid templates (0.5 μg/μl) were subjected to in 
vitro transcription using 3 U/μl T7 RNA polymerase (Thermo Fisher Scientific), transcription buffer II 
(Ethris GmbH), 1 U/µl RiboLock RNase inhibitor (Thermo Fisher Scientitic), 0.015 U/μl inorganic 
pyrophosphatase 1 (Thermo Fisher Scientific) with a defined choice of natural and chemically 
modified ribonucleotides (Jena Biosciences).  
RNA with modification set 1 was synthesized using 5-methylcytidine (25%) and 2-thiouridine (25%), 
in addition to unmodified nucleotides. For modification set 2, instead of 5-methylcytidine (25%) and 
2-thiouridine (25%), 5-iodouridine (35%) and 5-iodocytidine (7.5%) were used. The complete IVT-mix 
was incubated at 37°C for 2h. Afterward, 0.01 U/μl DNase I (Thermo Fisher) was added for an 
additional 45 min at 37°C to remove the plasmid template. RNA was precipitated with ammonium 
acetate at a final concentration of 2.5 mM, followed by two washing steps with 70% ethanol. The 
pellet was re-suspended in aqua ad injectabilia. A C1-m7G cap structure was added enzymatically by 
0.5 mM Vaccinia Virus Capping Enzyme (NEB) to the 5' end of the previously denatured transcript (1 
mg/ml) at 80°C for 5 min. The capping reaction mix contained 1x capping buffer (NEB), 0.5 mM GTP 
(NEB), 0.2 mM S-methyladenosine (NEB), 2.5 U/µl mRNA Cap 2ˈ-o-Methyltransferase (NEB) and 1 
U/µl RiboLock RNase Inhibitor (Thermo Fisher Scientific). The capping mixture was incubated for 60 
min at 37°C, followed by RNA precipitation with ammonium acetate at a final concentration of 2.5 
mM and two washing steps with 70% ethanol. The pellet was re-suspended in aqua ad injectabilia. 
RNA quality and concentration were measured spectrophotometrically on a NanoDrop2000C 
(Thermo Fisher Scientific). Its correct size and purity were determined via automated capillary 
electrophoresis (Fragment Analyzer, Advanced Analytical). 
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5.2.3. Cell culture 
A549 (ACC-107) and HEK293 (ACC-305) cells were purchased from DSMZ. 16HBE14o- cells were 
kindly provided by Prof. Weber (University of Münster, Germany). 
All cells were cultivated in Minimum Essential Media (MEM) with Glutamax (Gibco/Life 
Technologies). Media were supplemented with 10% heat-inactivated fetal bovine serum (FBS; 
Gibco/Life Technologies) and 1% penicillin/streptomycin (Gibco/Life Technologies). Cells were 
cultured in a humidified 5% CO2 incubator at 37°C.  
 
5.2.4. In vitro transfection  
A549 and HEK293 cells were seeded at the density of 2x104 cells/well and 4x104 cells/well 
respectively in a 96 well plate, for the purpose of firefly luciferase, FACS measurements, and EPO 
ELISA assay. 16HBE14o- cells were seeded in a 6-well plate at the density of 7.5x105 cells/well, for the 
purpose of Western blot analysis. At 24 hours post-seeding, cells were transfected with specific 
mRNAs using the commercial transfection reagent Lipofectamine®2000 (Thermo Fischer Scientific). 
Complexes were prepared at a ratio of 2 μl Lipofectamine®2000 per 1 μg mRNA. A549 cells were 
transfected with a dose of 250 ng/well. In HEK cells, transfections were performed using two doses: 
250 and 125 ng/well mRNA. For experiments in A549 and HEK293 cells, required amounts of mRNA 
were diluted in water and the needed amounts of Lipofectamine®2000 in serum-free MEM. mRNA 
was added to the Lipofectamine®2000 solution followed by 20 min incubation at RT. The 
concentration of the final mRNA/Lipofectamine®2000 solution was 25 ng/μl and 12.5 ng/μl. 10 μl of 
the complex solution was added to the cells and cells were incubated for 24 h. For every mRNA 
construct, replicates of three or six were prepared. For 16HBE14o- cells, 
Lipofectamine®MessengerMax was used due to its superior transfection efficiency (data not shown). 
For transfection, 7.5 µg mRNA was diluted in 125 µl water, and 11.25 Lipofectamine®MessengerMax 
separately in 125 µl serum-free MEM. The mRNA solution was added to the 
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Lipofectamine®MessengerMax solution followed by 5 min incubation time at RT. A total volume of 
250 µl of the lipoplex solution was added to the cells containing 2 ml normal growth media. The 
media was changed 4h after transfection.  
 
5.2.5. Flow cytometry analysis for d2EGFP 
Cells were washed with PBS, detached with TrypLE (Gibco/Life Technologies), and re-suspended in 
flow cytometry buffer (PBS supplemented with 10% FBS). Shortly before measurement, cells were 
stained with propidium iodide for discrimination between live and dead cells (1 μg/mL; Sigma 
Aldrich). The analysis was performed on an Attune Acoustic Focusing Cytometer (Life Technologies) 
with Attune Cytometric Software (version 2.1; Life Technologies) and FlowJo (version 10).  
 
5.2.6. Firefly Luciferase Assay  
For detection of firefly luciferase activity, the assay was performed 24h post-transfection. Cells were 
washed with PBS, followed by addition of 100 µl lysis buffer (25 mM Tris-HCl, 0.1% TritonX-100, pH 
7.4). Cells were shaken for 20 min at room temperature. After lysis, 50 µl of the cell lysate was used 
to measure luciferase activity via photon luminescence emission for 5 s using InfiniteR 200 PRO 
(Tecan). The protein amount in each sample was quantified in 5 µl of the cell lysate with BioRad 
protein assay (Bio-Rad), using bovine serum albumin as a standard. Luciferase values were 
normalized to the protein concentrations.  
 
5.2.7. Western Blot Analysis for human CFTR 
Cells, washed with PBS and collected into a tube were lysed with RIPA buffer for 30 min on ice (50 
mM Tris, pH 8.0, 150 mmol/L NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and 0.1% sodium 
dodecyl sulfate), followed by a 10 min centrifugation at 4°C. Total protein amount from the 
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supernatant was determined by the bicinchoninic acid (BCA) assay, following the manufacturer’s 
instructions (Thermo Fisher Scientific). Cell lysates were separated on 3%-8% TRIS-Acetate gels 
(Thermo Fisher Scientific) and transferred to polyvinylidene fluoride (PVDF) blotting membranes (Bio-
Rad). Membranes were blocked in Western Breeze blocking buffer (Thermo Fisher Scientific) and 
probed with antibodies against CFTR (R&D Systems MAB25031; 1:2.000) and Hsp90 (Origene 
TA500494; 1:15.000). Horseradish peroxidase (HRP)-conjugated anti-mouse antibody (1:10.000; 
ab6820; Abcam) was used as secondary antibody. Blots of CFTR were developed using Super Signal 
West Femto (Thermo Scientific), and of Hsp90 using Luminata Forte Western HRP Substrate 
(Millipore).  
 
5.2.8. Enzyme-linked immunosorbent assay for hEPO 
Quantification of hEPO protein in cell supernatants was performed using human Erythropoietin 
Quanktine IVD ELISA kit (R&D Systems) following manufacturer’s instructions.  
 
5.2.9. RNA isolation and reverse transcription 
RNA was isolated at different time points post-transfection using Single Shot Cell Lysis kit (Bio-Rad) 
following manufacturer’s protocol. From the lysates (1 μg of RNA), cDNA was synthesized using 
iScript Select cDNA Synthesis kit (Bio-Rad) with oligo(dT) primers following the manufacturer’s 
instructions. The synthesized cDNA was stored at -20°C.  
 
5.2.10. Quantitative real-time Polymerase Chain Reaction (qPCR) 
Real-time qPCR was performed with short hydrolysis probes for d2EGFP and Luciferase targets 
(Universal Probe Library #37 and #29; Roche) on a Roche Light Cycler 96 (Roche Diagnostics). For 
d2EGFP, the following primers were used: 5’-cctgaagttcatctgcacca-3’and 5’-ctcgtgaccaccctgacc-3’. 
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Luciferase mRNA was quantified using the following primer, 5’-acgccgagtacttcgagatg-3’ and 5’-
attcagcccatagcgcttc-3’. Absolute mRNA values were calculated by interpolation from the standard 
curve. The dilutions for the standard curve were made using IVT mRNA in 1:10 ratio, starting with the 
concentration of 1 ng/µl to 1x10-5 ng/µl. 1 µl of each standard was mixed with 3 µl of untransfected 
cells, collected at the last time point, and reversely transcribed.  
 
5.2.11. Statistical analysis 
Each experiment was performed with at least three technical replicates per sample. Results are 
shown as means ±SD unless otherwise stated. Statistical analysis was performed using GraphPad 
Prism software (version 6). Data were tested for normal distribution using D’Agostino-Pearson 
omnibus normality test. Multiple comparisons were conducted by two-way ANOVA, followed by 
Sidak’s test (pairwise comparison) or Dunnett’s test (many-to-one comparison). A p-value ≤ 0.05 was 
considered statistically significant. 
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5.3.1. Design of modified / segmented poly(A) tails 
For the purpose of producing recombinant RNA with segmented poly(A) tails, the corresponding DNA 
sequences were cloned downstream of the gene of interest into a circular plasmid vector. 
Segmented poly(A) constructs including their separator attributes, tested in the current study are 
schematically presented as Figure 16. The most conventionally used poly(A) tail, comprising of 120 
adenosines (poly(A)120) was used as a benchmark72,73,77,84,126,133. It was split into either two or three 
segments of As. Two equal segments separated by 6 nucleotides contained 60 As each (poly(A)2x60_6). 
In the case of three equal segments, each segment comprised of 40 As and a separator of 6 
nucleotides among each of the segment (poly(A)3x40_6). With an aim of exploring the effect of the 
spacer between the two segments of 60 As, five additional constructs were made with variable 
length of the spacer: 12 nucleotides (poly(A)2x60_12), 24 nucleotides (poly(A)2x60_24) or a single 
nucleotide (poly(A)2x60_C, poly(A)2x60_G, poly(A)2x60_T). 
 
 
Figure 16. Schematic representation of all combinations of Poly(A) modifications tested in the current study.  
Different homo- or hetero-polymeric poly(A) stretches were inserted downstream of the gene of interest (GOI). 
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5.3.2. Segmented poly(A) tails drastically reduce recombination of poly(A) containing plasmids in 
E.coli 
The main reason for technical difficulties during a large-scale DNA template production with encoded 
poly(A) tail of sufficient length is instability of poly(A) containing sequences in circular plasmids134,135. 
Here, it was investigated if the application of mRNA containing segmented poly(A) tails offered any 
advantages with regard to plasmid recombination after transformation into E.coli, compared to a 
benchmark Poly(A)120. The purpose was to see if the results of reduced recombination are sequence-
dependent or can be widely applied to different sequences. Coding sequences (ORF) of three 
different genes (hEPO: 0.7 kb, d2EGFP: 0.9 kb, Luc2: 1.7 kb) were combined with each of the three 
poly(A) formats, poly(A)120, poly(A)2x60_6, and poly(A)3x40_6 and cloned into a pUC57-Kanamycin 
(Genescript) vector. Clones with insert were screened for the stability of the poly(A) region via 
restriction digestion of the poly(A) region and resolving its size via capillary gel electrophoresis 
(fragment analyzer). Figure 17 shows the distribution of recombinant clones for each of the three 
tested poly(A) constructs. More than 50% of the clones containing homologous poly(A) tail, 
poly(A)120, recombined. Use of segmented poly(A) significantly reduced recombination of plasmids 
with the strongest effect seen for poly(A)2x60_6 with less than 20% recombined clones. As a similar 
trend was observed with all three ORF sequences, this effect appears to be sequence independent. 
Figure 17. Quantification of poly(A) tail recombination for 
A120 and segmented poly(A) tails of poly(A)3x40_6 and 
poly(A)2x60_6.  
 
Significantly reduced recombination of the poly(A) region 
was observed using segmented poly(A) tails. n: a total 
number of clones of d2EGFP, luciferase and hEPO 
sequences tested with a particular poly(A) format. 
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5.3.3. Effects of poly(A) segmentation on mRNA productivity 
Reduced recombination of plasmids with segmented poly(A)s was the driver to further explore these 
constructs with respect to stability and translation efficiency of the resulting mRNAs. Destabilized 
EGFP with a relatively short protein half-life (d2EGFP) was chosen as a reporter protein for these 
initial studies. ORF sequence of d2EGFP was cloned into vectors containing different poly(A) formats. 
IVT mRNA was produced using modification set 1, using previously described protocols.77,136 A549 
cells were transfected with the mRNA, and at four different time points post-transfection (4, 24, 48 
and 72h), the protein, as well as mRNA levels, were quantified. Since d2EGFP is a fluorescent protein, 
its quantitation was accessed using FACS, and mRNA was quantified with quantitative real-time 
reverse transcriptase PCR (qPCR). Comparable levels of d2EGFP protein were observed at all four 
time-points (Figure 18, a) for the compared poly(A) formats. mRNA decay kinetics were comparable 
for the three poly(A) formats at all time points, except at 24h post-transfection (Figure 18, b) where 
significantly higher amounts of mRNA could be quantified for the A120 format. Protein and mRNA 
amounts were used to calculate mRNA productivity, defined as the amount of protein (d2EGFP 
fluorescence intensity) normalized to the amount of mRNA (quantified via qPCR), for the compared 
constructs. At earlier time points (4h, 24h), segmented poly(A) mRNA was more productive than the 
one furnished with homogeneous poly(A) tail (Figure 18, c) resulting in 50-70% more protein per 
mRNA molecule. 
SEGMENTATION OF THE POLY(A) TAIL 
 
57 
 
Figure 18. Determination of d2EGFP protein expression and mRNA decay kinetics of different poly(A) containing d2EGFP 
mRNAs post-transfection in A549 cells.  
(a) Median fluorescence intensity at 4, 24, 48 and 72h post-transfection, measured by FACS in A549 cells. (b) d2EGFP mRNA 
decay kinetics in A549 cells. (c) mRNA productivity was calculated by dividing the median fluorescence intensity (FACS data; 
a) by the mRNA amounts (real-time PCR data; b) and normalizing these ratios to those observed with poly(A)120 construct. 
Statistical significance was assessed by two-way ANOVA test with p-values: *p<0.5, **p<0.01, ***p<0.001, ****p<0.0001, 
n=3.   
 
 
To rule out sequence dependency of the observed data with d2EGFP, the different poly(A) formats 
(poly(A)2x60_6, poly(A)3x40_6 vs. poly(A)120) were also investigated using luciferase. Besides sequence, 
nucleotide modifications have also been shown to influence the functionality of non-coding 
sequence elements in mRNA79. For this reason, in subsequent experiments with luciferase both 
unmodified and modified (using modification set 1 and modification set 2) mRNAs were tested. A549 
cells were transfected with corresponding luciferase-encoding mRNA, transcribed in all three 
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different nucleotide modifications; unmodified, modification 1 and modification 2.136 Luciferase 
expression and mRNA decay kinetics for each construct were determined at 24h post-transfection. 
The time point was chosen based on the d2EGFP data where the maximum difference in mRNA half-
life and productivity were seen at 24 h post mRNA delivery. In this experiment, in addition to A120, 
the performance of segmented poly(A) constructs was additionally compared to a previously 
published construct79 comprising homopolymeric A stretch (A63), homopolymeric C stretch (C31) and 
histone stem-loop (Figure 19). Luciferase activity was significantly increased in a modification-
independent manner when the cells were transfected with segmented poly(A)2x60_6, compared to 
homogeneous poly(A)120 and ACH benchmark (Figure 19). qPCR revealed that the differences 
between the mRNA amounts for the different poly(A) tail containing luciferase mRNAs, including 
different modifications, was only moderate. These data taken together demonstrated that the most 
productive construct was segmented poly(A)2x60_6 if transcribed in modification sets 1-2. ACH 
construct resulted in significantly lower luciferase protein and mRNA productivity across all three 
types of mRNAs (unmodified and modified) compared to poly(A) containing constructs. 
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Figure 19. Determination of luciferase expression and mRNA decay kinetics of different poly(A) containing luciferase mRNA 
24h post-transfection in A549 cells.  
(a) Luciferase activity in protein lysates from A549 cells transfected with different poly(A) containing luciferase RNA 
measured 24h post-transfection. (b) Luciferase mRNA quantification in A549 cells. (c) mRNA productivity was calculated by 
dividing the luciferase expression values (RLU; a) by the mRNA amounts (real-time PCR data; b) and normalizing these ratios 
to those observed with Poly(A)120 construct. Statistical significance was assessed by two-way ANOVA test with p-values: 
*p<0.5, **p<0.01, ***p<0.001, ****p<0.0001, n=6. 
 
 
5.3.4. Effects of poly(A) segmentation on the translation of physiological targets 
Due to encouraging results from previous experiments using segmented poly(A) tails in a 
combination with intracellular reporter proteins, such as d2EGFP and luciferase, the concept of 
poly(A)2x60_6 was further tested in physiological targets. Human EPO was selected as an example of a 
secretory protein (length of a coding region of 0.9 kb). As an example of a membrane protein, human 
cystic fibrosis transmembrane conductance regulator (CFTR) with a coding region of 4.5 kb was used. 
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Codon-optimized sequence (optimized using GeneOptimizer) for hEPO was cloned upstream of the 
poly(A)120 or poly(A)2x60_6 version of the tail, in the pUC57-Kanamycin vector. The resulting plasmids 
were used as a template for mRNA production via in vitro transcription incorporating unmodified, 
modification 1 or modification 2 sets of nucleotides. Transfection experiments were performed in 
human HEK293 cells with two different doses of mRNA (250ng/well and 125ng/well). At three time 
points post-transfection (24h, 48h, 72h), EPO protein concentrations were determined via ELISA. As 
Figure 20 shows, among the compared poly(A) formats at any of the applied doses, time points or 
modifications, no significant difference in protein expression was observed. An exception of this 
observation is the expression of unmodified mRNA at 24h and 72h post-transfection and mRNA in 
modification set 1 at 72h.  
 
Figure 20. Quantification of secreted human erythropoietin protein levels as measured via ELISA in supernatants from 
HEK293 cells transfected either with poly(A)120 or poly(A)2x60 containing EPO mRNA at 24h (a), 48h (b) and 72h (c) post-
transfection.  
Values represent mean ± SD of three replicates.  Statistical significance was assessed by two-way ANOVA test with p-values: 
**p<0.01, ***p<0.001, n=3. 
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As an example of a transmembrane protein, codon optimized sequence for human CFTR coding 
sequence was cloned upstream of either poly(A)2x60_6 or poly(A)120 variant of the poly(A) tail. 
16HBE14o- cells were transfected with unmodified IVT mRNA, and cells were lysed for the further 
procedure of Western blotting after 24h and 48h. The expression of CFTR was compared to 
expression of a housekeeper gene Hsp90, to obtain a normalized value of the expression. This 
experiment lead to similar observation as already seen with previous protein targets; comparable 
protein expression levels from both the compared poly(A) formats (Figure 21). 
 
Figure 21. Relative quantification of CFTR protein in 16HBE14o- lysates as measured via Western blot.  
16HBE14o- cells were transfected either with poly(A)120 or poly(A)2x60_6 containing hCFTR mRNA and protein lysates analyzed 
at 24 and 48h post-transfection. (b) Densitometry analysis of western blot images. Values represent mean ± SD of two 
replicates. Statistical significance was assessed by paired t-test with p-values: ns = p˃0.5. 
 
 
5.3.5. Spacer region expansion in poly(A)2x60 
After getting confirmation from the results with physiological genes, that segmented poly(A) with 6 
nucleotides as a spacer between the segments does not negatively affect translation, the effects of 
different spacer lengths were tested. As the starting point, the spacer was expanded from 6 
nucleotides (poly(A)2x60_6), to 12 (poly(A)2x60_12) and 24 nucleotides (poly(A)2x60_24). Three constructs 
harboring luciferase coding region upstream of poly(A) tail were cloned, and further in vitro 
transcribed into mRNAs as unmodified and in modification set 1-2. Transfection was done in A549 
cells, and measurements were performed 24h post-transfection. Observing the results at 
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unmodified- and modification 1- contacting mRNA, longer spacers express significantly lower 
amounts of luciferase (Figure 22). Comparable levels of luciferase mRNA could be quantified in the 
cells for all constructs regardless of modification, with a single exception. The same applies to mRNA 
productivity. Segmented poly(A) tails with an increased spacer length of more than 6 nucleotides did 
not result in any significant advantage, neither in translation efficiency nor in mRNA stability. 
 
 
Figure 22. Determination of luciferase expression and mRNA quantification of different poly(A) containing luciferase mRNA 
at 24h post-transfection in A549 cells.  
(a) Luciferase activity in protein lysates from A549 cells transfected with different poly(A) containing luciferase mRNA. (b) 
Luciferase mRNA quantification in A549 cells transfected with different poly(A) containing luciferase mRNA. (c) mRNA 
productivity was calculated by dividing the luciferase expression values (RLU; a) by the mRNA amounts (real-time PCR data; 
b) and normalizing these ratios to those observed with Poly(A)120 construct. Statistical significance was assessed by two-way 
ANOVA test with p-values: *p<0.5, **p<0.01, ****p<0.0001, n=6. 
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5.3.6. Spacer region reduction in poly(A)2x60 
With a similar idea in mind as described above, the effect of reducing the spacer length to a single 
nucleotide in segmented poly(A)2x60 tail on protein expression and mRNA productivity was examined. 
As the variability of options is limited by the number of nucleotides available in naturally occurring 
constructs, we created three new constructs, each harboring either C, T or G as a spacer nucleotide 
between two poly(A) segments in the tail. Also, mRNAs in unmodified, and both modification 
versions (modification 1 and 2) were produced by IVT and used for transfection of A549 cells. 
Expression levels, measured at 24h post-transfection were benchmarked to a standard, 
homogeneous poly(A)120. As seen from Figure 23, all three constructs resulted in higher luciferase 
expression when compared to poly(A)120, regardless of the spacer nucleotide or modification choice. 
Most of the mRNAs quantified from each construct were at comparable levels. Considering the 
mRNA productivity, all the constructs with segmented poly(A) were more productive than 
homogeneous poly(A)120. 
 
Figure 23. Determination of luciferase expression and mRNA quantification of different poly(A) containing luciferase mRNA 
at 24h post-transfection in A549 cells.  
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(a) Luciferase activity in protein lysates from A549 cells transfected with different poly(A) containing luciferase mRNA. (b) 
Luciferase mRNA quantification in A549 cells transfected with different poly(A) containing luciferase mRNA. (c) mRNA 
productivity was calculated by dividing the luciferase expression values (RLU; a) by the mRNA amounts (real-time PCR data; 
b) and normalizing these ratios to those observed with Poly(A)120 construct. Statistical significance was assessed by two-way 
ANOVA test with p-values: *p<0.5, ****p<0.0001, n=6. 
 
In contrast to luciferase expression where no difference was observed between the three single 
nucleotide spacers, choice of the spacer nucleotide influenced recombination efficiency of the 
poly(A) tail in E.coli. Highest recombination rate, comparable to values observed with poly(A)120 
(approx. 50%) was seen when C was used as a spacer in contrast to no recombination with G as single 
nucleotide spacer between the two segments (Figure 24).  
 
Figure 24. Quantification of poly(A) tail recombination rate for segmented poly(A) tails with a single nucleotide spacer.  
n: a total number of clones of luciferase tested with a particular poly(A) format. 
 
Taken together, these results show that segmented poly(A)2x60 with either a 6 or a single nucleotide 
(G/T) spacer offers advantages for use in RNA production by plasmid-based vectors. Due to their 
reduced recombination rate compared to conventionally used poly(A)120, they could significantly 
simplify the DNA template production with template-encoded poly(A) tails. Moreover, they did not 
show any negative effect on protein expression and mRNA half-life. 
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The motivation for segmenting the poly(A) tail into smaller fragments separated by spacer elements 
arose after technical difficulties during the DNA template production. As the most common poly(A) 
tail is composed of 120 adenosines, its length served as the basis for segmenting the poly(A) tail. The 
constructs were segmented into either two or three parts, each comprising an equal number of 
nucleotides. In the case of 2 segments, each part contained 60 adenosines (poly(A)2x60_6), and each of 
the 3-part poly(A) contained 40 adenosines (poly(A)3x40_6). Restriction site of NsiI was used as a spacer 
of 6 nucleotides. With this approach, a physical distance between two polyadenosine sequences and 
the restriction site could still be used to check the size of each fragment. Another reason for keeping 
the minimum length of 40 nucleotides per segment is to enable the binding of multimers of PABP. It 
has been reported that a minimum of 12 adenosines is needed for the binding of a single PABP 
molecule129–131, but also that a monomer of PABP, although binding to eIF4 complex, was not enough 
to support translation128. Therefore, poly(A)3x40_6 and poly(A)2x60_6 segments were designed to be long 
enough to host at least three PABPs per segments.  
OFRs of target proteins, namely luciferase, d2EGFP, hEPO and CFTR were cloned upstream of 
different poly(A) variations. Purified ligations were transformed into a DH10B bacterial strain of E.coli 
and tested for insert and poly(A) length. Screening of the insert positive clones containing the 
poly(A)120 format revealed that approximately 50% had shorter poly(A) than 120 adenosines 
implicating recombination in the homopolymer poly(A). Comparable rates of poly(A) recombination 
have been reported by Grier et al 2016.127 The recombination was also shown to be sequence 
independent. However, constructs with segmented poly(A)2x60_6 had a 2-fold reduced rate of 
recombination. Considering the translation efficiency of the poly(A)2x60_6 in d2EGFP, it resulted in 
comparable values to those observed with poly(A)120, and the stability of the mRNA was not affected. 
Apart from the conventionally used poly(A)120 format, the segmented poly(A) was additionally 
compared to ACH, published by Thess et al.79 It is composed of a homopolymeric A stretch, a 
homopolymeric C stretch, and a histone stem-loop. The functions of poly(A) are overtaken by the 
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conserved stem-loop 137,138. This approach was tested in the experiments with luciferase, and 
significantly higher expression was observed with the usage of poly(A)2x60_6 than either ACH or 
poly(A)120. There were no significant effects on mRNA stability. 
Encouraged with the results observed with reporter proteins (d2EGFP, luciferase), the next step was 
to investigate the segmented poly(A)2x60_6 effect on translation of physiological genes. A different 
class of proteins was chosen since both luciferase and d2EGFP are intracellularly localized. As an 
example of a secretory protein, EPO was chosen. It is normally secreted by the kidney and stimulates 
the production of red blood cells. CFTR, which serves as an ion channel conducting chloride and 
thiocyanate ions was selected as an example of a transmembrane protein. Its function is impaired in 
patients suffering from cystic fibrosis. Regarding the translated proteins detected post-transfection in 
relevant cell lines with respective mRNAs differing in the poly(A) format, no significant differences 
could be observed with any of the physiological targets. The same trend was observed regardless of 
the time point and the usage of modifications when EPO was used as a target protein. In the case of 
CFTR, experiments were performed only using unmodified mRNA, because a recent study132 has 
demonstrated functional restoration of CFTR in human CF airway epithelia after transfection with 
unmodified CFTR mRNA.  
Further, the varying length of the spacer positioned between the A segments and its effect on 
protein expression and recombination was investigated with luciferase as a reporter gene. When the 
length of the spacer was increased from 6 nucleotides to 12 or 24 nucleotides, no specific advantages 
could be observed. Rather, if using modification 1 and prolonged spacers, protein expression was 
lower than with segmented poly(A)2x60_6. A possible explanation for such an outcome with modified 
mRNA is that incorporation of the modified nucleotides within the spacer region could affect the 
binding of poly(A) binding protein to the two segments of poly(A). Reduction of the spacer length to 
a single nucleotide significantly increased protein expression, regardless of chosen nucleotide (T, C or 
G), when compared to poly(A)120. mRNA quantification confirmed comparable levels for all the three 
spacers. This implies that segmented poly(A) with single nucleotide spacer positively affected mRNA 
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translation. Considering recombination rates of constructs with single nucleotides, the reduction of it 
was observed. As recombination with poly(A)2x60_6 was already lower (20% compared to 50% with 
poly(A)120), incorporation of a single G as a spacer further reduced it to zero.  
All these results taken together imply that the use of segmented poly(A)2x60 with either 6 or 1 
nucleotide spacer (G/T), cloned into plasmid vectors, significantly reduces recombination in E.coli 
without negatively affecting translation and mRNA stability when compared to the relatively unstable 
and widely used poly(A)120. 
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A general procedure of mRNA production for therapeutic purposes involves either a PCR or a plasmid 
DNA template containing all of the necessary elements, such as the coding sequence, UTRs, and 
poly(A) tail. When a homopolymeric stretch such as poly(A) is cloned into a conventional plasmid 
vector, a common phenomenon is its recombination and therefore shortening. This is a major risk 
which limits the use of plasmid DNA vectors containing poly(A) tails form large-scale RNA production. 
A promising approach to target this issue is splitting the poly(A) tail into 2 segments, each consisting 
of 60 adenosines, separated by a spacer element. Using such a segmented poly(A) significantly 
reduced recombination of the plasmid in E.coli and mRNAs containing such segmented poly(A)s were 
comparable in terms of their translation efficiency and intracellular stability. These effects were 
independent of sequence and nucleotide modification(s) used in the mRNA production reactions and 
as such present segmented poly(A) as a promising variation of the poly(A) tail for the ease of plasmid 
production. 
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In the first part of the work, it was shown that use of minimal 5’-UTRs yielded to higher protein 
expression. These UTRs were designed by taking only those sequence elements which were needed 
for transcription (T7 promoter), and translation (translation regulator). The results from this section 
highlight the superior performance of such short synthetic 5’-UTRs over naturally occurring, long 5’-
UTRs. The latter, due to their longer sequence are often susceptible to structural changes upon 
incorporation of chemically modified nucleotides, are cell-specific and their performance is often 
influenced by the downstream sequence79 which was not the case with minimal 5’-UTRs.  
Segmented poly(A) tails significantly reduce recombination in E.coli during plasmid amplification 
without affecting either the half-life or translation of the in vitro produced mRNA using such plasmids 
as template. Based on these findings, its incorporation into the standard DNA-template design would 
ease everyday procedure and significantly reduce the time invested in screening and finding the 
clones of the right length. 
The research presented in this thesis has opened a number of research-based and pragmatic 
questions that should be addressed in the future. In Chapter 4, a high performance of short synthetic 
5’-UTRs were demonstrated by both, in vitro and in vivo experiments. The actual potential of these 
synthetic minimalistic UTR sequences for transcript therapies would be confirmed in disease animal 
models using physiological genes impaired in metabolic diseases. The innovative approach towards 
plasmid-based templates for in vitro RNA production by segmenting the poly(A) tails was described in 
Chapter 5. With respect to that, a future focus should be put into understanding the molecular 
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mechanism behind reduced recombination of segmented poly(A) tails. In line with a broader scope of 
transcript therapies, such approaches may provide an attractive platform to simplify 5’-UTR mRNA 
design and to facilitate DNA-based template production with encoded poly(A) tail.  
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Table 15. 5’-UTR sequences used in this study 
5’-UTR  5’-UTR sequence 
UTR1 GGGAGAGCCACC 
UTR2 GGGAGACGCCACC 
UTR3 GGGAGACTGCCACC 
UTR4 GGGAGACAGCCACC 
UTR5 GGGAGACCGCCACC 
UTR6 GGGAGACGGCCACC 
UTR7 GGGAGACTGCCAAG 
refUTR1 GGGAGACTCTTCTGGTCCCCACAGACTCAGAGAGAAC 
refUTR2 GGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCGGGAACGG
TGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACTCACCGTCCTTGACACG 
refUTR3 GGGAGACAAAAAAAAAAAAAAAAAAAA 
refUTR4 GGGAGACCATATTGAAGAGACAGAGTGATATATAAAACTGCTAA 
refUTR5 GGGAGACAAAACTGCTAA 
 
 
Table 16. Poly(A) sequences used in this study 
Poly(A) Poly(A) sequence 
2x60_6 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
3x40_6 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAGATATCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
A120 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
ACH79 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATGCATCCCCC
CCCCCCCCCCCCCCCCCCCCCCCCCC 
2x60_C AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
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2x60_G AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
2x60_T AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAATAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
2x60_12nt AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACGCCATTAGAGGAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
2x60_24nt AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACAACCCCTGATTGT
GTCCGCATCTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
 
 
Table 17. GOI sequences used in this study 
GOI Sequence 
Luc2 ATGGAAGATGCCAAAAACATTAAGAAGGGCCCAGCGCCATTCTACCCACTCGAAGACGGGACCGCCGGCGAGCAG
CTGCACAAAGCCATGAAGCGCTACGCCCTGGTGCCCGGCACCATCGCCTTTACCGACGCACATATCGAGGTGGACA
TTACCTACGCCGAGTACTTCGAGATGAGCGTTCGGCTGGCAGAAGCTATGAAGCGCTATGGGCTGAATACAAACCA
TCGGATCGTGGTGTGCAGCGAGAATAGCTTGCAGTTCTTCATGCCCGTGTTGGGTGCCCTGTTCATCGGTGTGGCT
GTGGCCCCAGCTAACGACATCTACAACGAGCGCGAGCTGCTGAACAGCATGGGCATCAGCCAGCCCACCGTCGTAT
TCGTGAGCAAGAAAGGGCTGCAAAAGATCCTCAACGTGCAAAAGAAGCTACCGATCATACAAAAGATCATCATCAT
GGATAGCAAGACCGACTACCAGGGCTTCCAAAGCATGTACACCTTCGTGACTTCCCATTTGCCACCCGGCTTCAACG
AGTACGACTTCGTGCCCGAGAGCTTCGACCGGGACAAAACCATCGCCCTGATCATGAACAGTAGTGGCAGTACCGG
ATTGCCCAAGGGCGTAGCCCTACCGCACCGCACCGCTTGTGTCCGATTCAGTCATGCCCGCGACCCCATCTTCGGCA
ACCAGATCATCCCCGACACCGCTATCCTCAGCGTGGTGCCATTTCACCACGGCTTCGGCATGTTCACCACGCTGGGC
TACTTGATCTGCGGCTTTCGGGTCGTGCTCATGTACCGCTTCGAGGAGGAGCTATTCTTGCGCAGCTTGCAAGACTA
TAAGATTCAATCTGCCCTGCTGGTGCCCACACTATTTAGCTTCTTCGCTAAGAGCACTCTCATCGACAAGTACGACCT
AAGCAACTTGCACGAGATCGCCAGCGGCGGGGCGCCGCTCAGCAAGGAGGTAGGTGAGGCCGTGGCCAAACGCT
TCCACCTACCAGGCATCCGCCAGGGCTACGGCCTGACAGAAACAACCAGCGCCATTCTGATCACCCCCGAAGGGGA
CGACAAGCCTGGCGCAGTAGGCAAGGTGGTGCCCTTCTTCGAGGCTAAGGTGGTGGACTTGGACACCGGTAAGAC
ACTGGGTGTGAACCAGCGCGGCGAGCTGTGCGTCCGTGGCCCCATGATCATGAGCGGCTACGTTAACAACCCCGA
GGCTACAAACGCTCTCATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCA
CTTCTTCATCGTGGACCGGCTGAAGAGCCTGATCAAATACAAGGGCTACCAGGTAGCCCCAGCCGAACTGGAGAGC
ATCCTGCTGCAACACCCCAACATCTTCGACGCCGGGGTCGCCGGCCTGCCCGACGACGATGCCGGCGAGCTGCCCG
CCGCAGTCGTCGTGCTGGAACACGGTAAAACCATGACCGAGAAGGAGATCGTGGACTATGTGGCCAGCCAGGTTA
CAACCGCCAAGAAGCTGCGCGGTGGTGTTGTGTTCGTGGACGAGGTGCCTAAAGGACTGACCGGCAAGTTGGACG
CCCGCAAGATCCGCGAGATTCTCATTAAGGCCAAGAAGGGCGGCAAGATCGCCGTGTAA 
 
hEPO ATGGGCGTGCACGAATGTCCTGCTTGGCTGTGGCTGCTGCTGAGCCTGCTGTCTCTGCCTCTGGGACTGCCTGTGCT
GGGAGCCCCTCCTAGACTGATCTGCGACAGCCGGGTGCTGGAAAGATACCTGCTGGAAGCCAAAGAGGCCGAGAA
CATCACCACCGGCTGCGCCGAGCACTGCAGCCTGAACGAGAATATCACCGTGCCCGACACCAAAGTGAACTTCTAC
GCCTGGAAGCGGATGGAAGTGGGCCAGCAGGCTGTGGAAGTGTGGCAGGGACTGGCCCTGCTGAGCGAAGCTGT
GCTGAGAGGACAGGCTCTGCTCGTGAACAGCAGCCAGCCTTGGGAGCCTCTGCAGCTGCACGTGGACAAGGCCGT
GTCTGGCCTGAGAAGCCTGACCACACTGCTGAGAGCCCTGGGGGCCCAGAAAGAGGCCATCTCTCCACCTGATGCC
GCCTCTGCCGCCCCTCTGAGAACCATCACCGCCGACACCTTCAGAAAGCTGTTCCGGGTGTACAGCAACTTCCTGCG
GGGCAAGCTGAAGCTGTACACAGGCGAGGCCTGCCGGACCGGCGATAGATAA 
 
d2EGFP ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGG
CCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACC
ACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACC
CCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTC
AAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTG
AAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTC
TATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGC
GTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACC
TGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGC
CGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGAAGCTTAGCCATGGCTTCCCGCCGGAGGTGGAGGAGCA
GGATGATGGCACGCTGCCCATGTCTTGTGCCCAGGAGAGCGGGATGGACCGTCACCCTGCAGCCTGTGCTTCTGCT
AGGATCAATGTGTAG 
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CFTR ATGCAGAGAAGCCCCCTGGAAAAGGCCAGCGTGGTGTCCAAGCTGTTCTTCAGCTGGACCCGGCCCATCCTGCGGA
AGGGCTACAGACAGAGACTGGAACTGAGCGACATCTACCAGATCCCCAGCGTGGACAGCGCCGACAACCTGAGCG
AGAAGCTGGAAAGAGAGTGGGACAGAGAGCTGGCCTCCAAGAAGAACCCCAAGCTGATCAACGCCCTGCGGCGG
TGCTTCTTCTGGCGGTTTATGTTCTACGGCATCTTCCTGTACCTGGGCGAAGTGACCAAGGCCGTGCAGCCTCTGCT
GCTGGGCAGAATCATTGCCAGCTACGACCCCGACAACAAAGAGGAACGGTCTATCGCCATCTACCTGGGCATCGGC
CTGTGCCTGCTGTTCATCGTGCGGACCCTGCTGCTGCACCCTGCCATCTTTGGCCTGCACCACATCGGCATGCAGAT
GCGGATCGCCATGTTCAGCCTGATCTACAAGAAAACCCTGAAGCTGAGCAGCCGGGTGCTGGACAAGATCAGCATC
GGACAGCTGGTGTCCCTGCTGAGCAACAACCTGAACAAGTTCGACGAGGGCCTGGCCCTGGCCCACTTCGTGTGGA
TTGCACCACTGCAGGTGGCACTGCTGATGGGCCTGATCTGGGAACTGCTGCAGGCCAGCGCCTTTTGCGGCCTGGG
CTTTCTGATTGTGCTGGCCCTGTTCCAGGCCGGACTGGGCCGGATGATGATGAAGTACCGGGACCAGAGAGCCGG
CAAGATCTCCGAGCGGCTCGTGATCACCAGCGAGATGATCGAGAACATCCAGAGCGTGAAGGCCTACTGCTGGGA
AGAGGCCATGGAAAAGATGATTGAGAATCTGCGGCAGACCGAGCTGAAACTGACCCGGAAGGCCGCCTACGTGCG
CTACTTCAACAGCAGCGCCTTCTTCTTCTCCGGCTTCTTCGTGGTGTTCCTGAGCGTGCTGCCCTACGCCCTGATCAA
GGGCATCATCCTGAGAAAGATTTTCACCACCATTTCTTTCTGCATCGTGCTGCGGATGGCCGTGACCAGACAGTTCC
CTTGGGCTGTGCAGACTTGGTACGACAGCCTGGGCGCCATCAACAAGATCCAGGACTTCCTGCAGAAGCAGGAGTA
CAAGACCCTGGAGTACAACCTGACCACCACCGAGGTCGTGATGGAAAACGTGACCGCCTTCTGGGAGGAAGGCTT
CGGCGAGCTGTTCGAGAAGGCCAAGCAGAACAACAACAACCGCAAGACCAGCAACGGCGACGACTCCCTGTTCTTC
TCCAACTTCTCCCTGCTGGGGACCCCCGTGCTGAAGGACATCAACTTCAAGATCGAGCGGGGACAGCTGCTGGCCG
TGGCTGGATCTACAGGCGCCGGAAAGACCAGCCTGCTGATGGTCATCATGGGCGAGCTGGAACCCAGCGAGGGCA
AGATCAAGCACAGCGGCCGGATCAGCTTCTGTAGCCAGTTCTCCTGGATCATGCCCGGCACCATCAAAGAGAACAT
CATCTTCGGCGTGTCCTACGACGAGTACAGATACCGCAGCGTGATCAAGGCCTGCCAGCTGGAAGAGGACATCAGC
AAGTTCGCCGAGAAGGACAATATCGTGCTGGGCGAGGGCGGCATCACACTGTCTGGCGGCCAGAGGGCCAGAATC
AGCCTGGCCAGAGCCGTGTACAAGGACGCCGATCTGTACCTGCTGGACAGCCCCTTCGGCTACCTGGACGTGCTGA
CCGAGAAAGAGATCTTCGAGAGCTGCGTGTGCAAGCTGATGGCCAACAAGACCCGGATCCTCGTGACCAGCAAGA
TGGAACACCTGAAGAAGGCCGACAAGATCCTGATCCTGCACGAGGGCAGCAGCTACTTTTACGGCACCTTCAGCGA
GCTGCAGAACCTGCAGCCCGACTTCAGCAGCAAACTGATGGGCTGCGACAGCTTCGACCAGTTCAGCGCCGAGCG
GCGGAACAGCATCCTGACCGAAACCCTGCACCGGTTCTCCCTGGAAGGCGACGCTCCTGTGTCCTGGACCGAGACA
AAGAAGCAGAGCTTCAAGCAGACCGGCGAGTTTGGCGAGAAGAGAAAGAACTCCATCCTGAACCCCATCAATAGC
ATCCGGAAGTTCAGCATCGTGCAGAAAACCCCCCTGCAGATGAACGGCATCGAAGAGGACTCCGACGAGCCCCTG
GAACGCAGACTGAGCCTGGTGCCTGATAGCGAGCAGGGCGAGGCCATCCTGCCCAGAATCTCCGTGATCAGCACC
GGCCCTACCCTGCAGGCTCGGAGAAGGCAGTCTGTGCTGAACCTGATGACCCACAGCGTGAACCAGGGACAGAAT
ATCCACAGAAAGACCACCGCCAGCACCAGAAAAGTGTCACTGGCCCCCCAGGCCAACCTGACAGAGCTGGACATCT
ACAGCAGACGGCTGAGCCAGGAAACAGGCCTGGAAATCAGCGAGGAAATCAACGAAGAGGATCTGAAAGAGTGC
TTTTTCGACGACATGGAATCCATCCCCGCCGTGACAACCTGGAATACCTACCTGCGGTACATCACCGTGCACAAGTC
CCTGATCTTCGTGCTGATCTGGTGTCTCGTGATCTTCCTGGCCGAGGTGGCCGCTTCTCTGGTGGTGCTGTGGCTGC
TGGGAAACACCCCTCTGCAGGACAAGGGCAACAGCACCCACAGCCGGAACAACAGCTATGCCGTGATCATCACAAG
CACCAGCTCCTACTACGTGTTCTACATCTACGTGGGCGTGGCCGACACCCTGCTGGCCATGGGCTTTTTCAGAGGCC
TGCCCCTGGTGCACACCCTGATCACCGTGTCCAAGATTCTGCACCATAAGATGCTGCACAGCGTGCTGCAGGCTCCC
ATGAGCACCCTGAATACCCTGAAGGCTGGCGGCATCCTGAATCGGTTCAGCAAGGACATTGCCATCCTGGACGACC
TGCTGCCTCTGACCATCTTCGACTTCATCCAGCTGCTGCTGATCGTGATCGGCGCCATTGCCGTGGTGGCTGTGCTG
CAGCCCTATATCTTCGTGGCCACCGTGCCCGTGATCGTGGCCTTCATTATGCTGCGGGCCTACTTTCTGCAGACCTCT
CAGCAGCTGAAACAGCTGGAATCCGAGGGCAGAAGCCCCATCTTCACCCACCTCGTGACAAGCCTGAAGGGCCTGT
GGACCCTGAGAGCCTTCGGCAGACAGCCCTACTTCGAGACACTGTTCCACAAGGCCCTGAACCTGCACACCGCCAA
CTGGTTTCTGTATCTGTCCACCCTGCGGTGGTTCCAGATGAGGATCGAGATGATTTTTGTGATCTTCTTTATCGCCGT
GACCTTCATCAGCATTCTGACCACCGGCGAGGGGGAGGGCAGAGTGGGCATTATTCTGACACTGGCCATGAACATC
ATGAGCACTCTGCAGTGGGCCGTGAACAGCTCCATCGACGTGGACTCCCTGATGCGGAGCGTGTCCCGGGTGTTCA
AGTTCATCGACATGCCCACAGAGGGCAAGCCCACCAAGAGCACCAAGCCCTACAAGAACGGCCAGCTGAGCAAAG
TGATGATTATCGAGAACTCCCACGTGAAGAAGGATGACATCTGGCCCAGCGGCGGACAGATGACCGTGAAGGATC
TGACCGCCAAGTACACCGAGGGCGGAAACGCCATTCTGGAAAACATCAGCTTTAGCATCTCTCCCGGCCAGCGCGT
GGGCCTGCTGGGACGGACAGGATCTGGCAAGTCTACCCTGCTGTCCGCCTTCCTGCGGCTGCTGAATACCGAAGGC
GAGATCCAGATCGACGGGGTGTCCTGGGACAGCATTACACTGCAGCAGTGGCGCAAGGCCTTTGGCGTGATCCCC
CAGAAGGTGTTCATTTTCAGCGGCACCTTTCGGAAGAACCTGGACCCCTACGAGCAGTGGAGCGACCAGGAAATCT
GGAAGGTGGCCGATGAAGTGGGACTGAGAAGCGTGATCGAGCAGTTTCCCGGCAAGCTGGATTTCGTGCTGGTGG
ACGGCGGCTGCGTGCTGTCTCACGGACACAAGCAGCTGATGTGCCTGGCTAGATCCGTGCTGTCCAAGGCCAAGAT
CCTGCTGCTGGACGAGCCTAGCGCCCACCTGGATCCCGTGACATACCAGATCATCAGACGGACACTGAAGCAGGCC
TTCGCCGATTGCACCGTGATCCTGTGCGAGCACCGGATCGAGGCCATGCTGGAATGCCAGCAGTTTCTCGTGATTG
AAGAGAACAAAGTGCGGCAGTACGACTCCATTCAGAAGCTGCTGAACGAGAGAAGCCTGTTCCGGCAGGCCATCTC
CCCCAGCGACAGAGTGAAGCTGTTCCCCCACCGGAACTCCAGCAAGTGCAAGTCCAAGCCCCAGATCGCCGCCCTG
AAAGAAGAAACCGAGGAAGAGGTGCAGGATACCCGGCTGTGA 
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Table 18. Primers used for qPCR 
Target gene # UPL (Roche Diagnostics) Sequence (forward) Sequence (reverse) 
Luc2 29 5’-acgccgagtacttcgagatg-3’ 5’-attcagcccatagcgcttc-3’ 
d2EGFP 37 5’-cctgaagttcatctgcacca-3’ 5’-ctcgtgaccaccctgacc-3’ 
 
 Curriculum Vitae 
 
87 
 
 
 
 
 
 
I would like to pay special thankfulness, warmth, and appreciation to the persons below who 
made my research successful and assisted me at every point to cherish my goal. 
My greatest appreciation goes to Prof. Carsten Rudolph and Prof. Christian Plank, for the given 
opportunity to become a part of the Ethris family. With their professional support and immense 
knowledge, I was inspired to conduct my research and present it here as a doctoral dissertation.  
I would like to extend my special thanks to Dr. Manish Aneja, who has supervised me all the way 
through with his bright mind, great ideas and limitless motivation. Besides, I could have not 
imagined having a better advisor and mentor, who has taught me to always look ahead and has 
provided his support in numerous ways. For all of these, forever I shall remain indebted to him 
and I am truly thankful for that. 
Assistance and introduction to Ethris’s “RNA world”, as unique as the RNA world indeed is, 
provided by Dr. Johannes Geiger, and is greatly appreciated. 
I am also thankful to all other members of the Ethris family, who provided a pleasurable working 
atmosphere and occasional meetups. It was a pleasure to work with you! 
My closest family, mom, dad, and sister have once again proven their role with all their sacrifices 
made on my behalf, encouraging my education and explorative mind from day one. With their 
support and understandings, I became who I am today. I am also thankful to all other family 
members who not only assisted me financially but also extended their support morally and 
 Curriculum Vitae 
 
88 
emotionally. My greatest luck is to have so many good friends, whom I, although scattered all 
over the globe, always felt close by. For being my day-to-day support during this period, and for 
bringing so much happiness and cherishment to my life, a heartfelt thanks to Alexey. 
